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ABSTRACT
EVIDENCE OF AN INFECTIOUS ASTHMA PHENOTYPE: CHLAMYDIA DRIVEN
ALLERGY AND AIRWAY HYPERRESPONSIVENESS IN PEDIATRIC ASTHMA
FEBRUARY 2013
KATIR K. PATEL, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Wilmore C. Webley

Asthma is the most common chronic respiratory disease affecting young children and
adults all over the world. An estimated 34.1 million Americans have reported asthma in their
lifetime and the disease costs ~US $56 billion dollars to treat each year. Current treatment is
based on a paradigm of asthma as a non-infectious atopic condition whose root cause is
inflammation. Chronically administered anti-inflammatory medications, primarily inhaled
corticosteroids (ICS), ameliorate asthma symptoms in many patients. However, up to 50% of
asthmatics, characterized by neutrophil infiltration, IL-17 secretion and increased risk of fatality
are refractory to ICS treatment. Chlamydia pneumoniae, a ubiquitous, obligate intracellular
pathogen with an innate propensity to persist and cause chronic infections, along with
Mycoplasma pneumoniae have been implicated in the development of chronic, refractory asthma.
C. pneumoniae infections are common in infants and young children, often coinciding with the
development of early onset asthma in the population.
These facts lead the Webley lab to evaluate the carriage of Chlamydia in pediatric
respiratory disease patients and the work confirmed that respiratory infections caused by
Chlamydia is a significant risk factor in asthma development and live Chlamydia was isolated
from the lungs of children with chronic asthma. However, the exact mechanism underlying
chlamydial involvement in the disease remained unknown and we believed that a better
understanding could shed important light on expanded treatment options and mechanisms of this
vii

infectious asthma phenotype. The work presented here provides new insight into how (1) early
life chlamydial infection can lead to asthma initiation and exacerbation (2) respiratory chlamydial
infection induces cellular and chemical immune responses that support asthmatic inflammation
(3) other respiratory pathogens (eg. Mycoplasma) can drive similar immunological responses
resulting in significant lung pathology.
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CHAPTER 1
RATE OF CHLAMYDIA TRACHOMATIS AND CHLAMYDIA PNEUMONIAE IN
PEDIATRIC RESPIRATORY INFECTIONS
Abstract
Background: An emerging body of evidence suggests that half of asthma in both children and
adults is associated with chronic lung infection. The aim of this study was to determine the
frequency of viable Chlamydia pneumoniae (Cp) and trachomatis (Ct) in the respiratory tracts of
pediatric patients with chronic respiratory diseases.
Methods: Bronchoalveolar lavage fluid (BAL) obtained from 182 children undergoing
bronchoscopy for clinical reasons, were assayed using PCR analysis, in vitro tissue culture and
immunofluorescence staining for the presence of Cp and Ct.
Results: Chlamydia-specific DNA was detected by PCR in 124/182 (68%) patients; 79 were
positive for Cp, 77 for Ct and 32 for both organisms; seventy-five patients had cultivable
Chlamydia. Ct DNA prevalence decreased, whereas Cp positivity generally increased with age.
Fifty-nine of 128 asthma patients and 16/54 non-asthmatics were Chlamydia culture-positive
[p=0.048]. When the patients were divided into inflammatory versus non-inflammatory airway
disease, there were 69/150 [46%] and 6/32 [18%] BAL samples with cultivable Chlamydia
respectively [p=0.005].
Conclusions: Viable Cp and Ct occur frequently in children with chronic respiratory diseases and
may be more prevalent in asthma patients. To our knowledge, this is the first report of viable Ct
in the lungs of children.

Introduction
Respiratory diseases represent a major cause of disability and mortality among all age
groups and races worldwide. They are also a leading cause of hospitalization and morbidity in
both adults and children especially in developing countries (1-3). Chronic respiratory diseases
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which include, asthma and chronic obstructive pulmonary disease [COPD], are just as prevalent
as acute forms of these disorders (2). In addition to known environmental and genetic
contributors, there is growing evidence that pathogenic microorganisms may play a role in
diseases such as asthma . It is often difficult, however to identify the etiologic agent(s) of these
respiratory infections due to a lack of standard diagnostic tools and the need for invasive
procedures such as lung aspirations or pulmonary biopsies in order to confirm diagnosis. The
worldwide increase in the incidence of asthma and the impact of the disease on public health,
however, has led to renewed interest and investigations into its etio-pathogenesis.
Ct and Cp are two of the most common members of the Chlamydiaceae family that infect
humans. Cp is thought to be responsible for 10-15% of community acquired pneumonia and 5%
of pharyngitis and sinusitis cases (7, 8). Approximately 50% of healthy young adults and 75% of
elderly persons have serological evidence of previous Cp infection (9). There is increasing
evidence that Cp may play a role in pediatric asthma onset as well as possible exacerbations of
asthmatic symptoms (10, 11). On the other hand, Ct has been recognized as a pathogen in
nongonococcal urethritis, salpingitis, endocervicitis, pelvic inflammatory disease, inclusion
conjunctivitis of neonates, follicular conjunctivitis of adults, infantile pneumonia and associated
diseases (12, 13). Vertical transmission of infection from mother to the infant may result in the
development of conjunctivitis and pneumonia (14, 15). In the past, multiple investigations of
pediatric pneumonia emphasized the importance of infections with Ct in infants between two
weeks and four months of age (16-18). While stringent prenatal screening in the US has greatly
reduced the number of cases of neonatal conjunctivitis, there have been reports that ocular
prophylaxis can fail to prevent neonatal chlamydial conjunctivitis and does not prevent
colonization or infection at other sites such as the lungs (3, 19). Approximately 5-22% of
pregnant women are thought to have Ct infection of the cervix, and 30-50% of neonates born to
infected mothers show culture evidence of infection. Of infected neonates, 15-25% present with
clinical conjunctivitis and nasopharyngitis that in some cases develops into neonatal pneumonitis
2

(9). Published reports have documented that many infants infected with Ct at birth remain
infected for months or years in the absence of specific antimicrobial therapy (20). Indeed, some
reports have suggested that wheezing may be another clinical expression of Ct infection and that
this organism should be routinely assayed for in children who wheeze but have no demonstrable
allergy and do not respond to the usual anti-asthmatic medications . We recently confirmed the
presence of Chlamydia in BAL samples from pediatric patients with various chronic respiratory
diseases using PCR and tissue culture techniques (22). In the work presented here using
established species specific PCR and culture techniques, we extend these investigations to an
examination of the prevalence of both Cp and Ct in BAL samples collected from pediatric
patients and show that both infectious Cp and Ct are frequently present in the lung washings from
children with chronic respiratory diseases and that both organisms may contribute to Chlamydiamediated pneumonitis.

Materials and Methods
Specimens
We conducted a prospective, consecutive, non-interventional, cohort analysis of patients with
various pulmonary disorders undergoing elective diagnostic bronchoscopy with BAL sample
collection in a group of 184 patients from a community based/academic hospital setting. Seventy
of these specimens were previously studied and reported on in a prior communication (22). Two
patients above the age of 20 were excluded from the study because of our inclusion criteria of 20
years old and below for this pediatric cohort based on AAP accepted criteria (23). Patients were
recommended for bronchoscopy because they all met the criteria of having severe, persistent
airway disease that was non-responsive to therapy. Residual BAL samples obtained from study
participants were de-identified in a HIPPA compliant manner and given alpha numeric codes
prior to laboratory analysis. Approval for the study was obtained from the Institutional Review
Board at Baystate Medical Center. Written, informed consent was obtained from the guardian of
3

each patient prior to inclusion in the study and patients were not contacted during the course of
the study nor were they made aware of the results of the investigation. BAL was collected as
previously reported (22, 24).

PCR Analysis
Genomic DNA was isolated from BAL samples and PCR performed as previously described
(22). Initially, isolated DNA was amplified using a 16S signature sequence to detect all strains of
Chlamydiales as previously reported (22, 25). Cp-specific PCR was performed using the
previously published primer pair Cpn 201 and 202 to generate a 207bp product (26), while Ctspecific PCR was performed using the P1 & Omp2 primer set that amplified a 1100bp segment of
the omp1 gene (27). The PCR products were separated by electrophoresis on a 2% agarose gel
and visualized by staining with ethidium bromide. Photographs were taken with the Syngene
GeneFlash gel documentation system [Syngene USA, Frederick, MD].

Culture
Cells from BAL samples were pelleted, rinsed with sterile phosphate buffered saline and lysed
with sterile glass beads in sucrose phosphate glutamate buffer [SPG]. Cultures were performed as
previously described and cells were stained with a 1:100 dilution of a rabbit anti-Chlamydia
antibody, [BIODESIGN International, Saco, ME] and visualized with a 1:1000 dilution of AlexaFluor®488 goat anti-rabbit secondary antibody [Invitrogen, Molecular Probes Carlsbad, CA].
The slides were then examined and photographs taken using a Zeiss LSM 510 Meta Confocal
System.

BAL Cell Counts
Upon recovery, BAL cell counts and differentials were performed according to standard
techniques

in

the

hospital’s

Hematology
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Clinical

Laboratory

at

Baystate

Medical Center (Springfield, MA). Cell enumeration was performed manually using a cell
counting chamber (hemacytometer, improved Neubauer) under phase microscopy with results
expressed as “number of cells per cubic millimeter”. BAL differential counts were performed
using Wright stained cytospin preparations of BAL which were then examined under oilimmersion microscopy (50X or 100X). Results were expressed on the basis of a 100 cell count
survey.

Statistics
Data were analyzed using Microsoft Excel® spread sheets as well as the SPSS 11.5 Graduate
Pack [SPSS, Inc., Chicago, IL] statistics programs. Cross-tabs with the Fisher exact T test and
Chi-Squared test were used to determine significance. Univariate and bivariate analyses as well as
logistic regression were also used to establish interactions between and among variables. For all
analyses, tests were two-sided, and the level of significance was p ≤ 0.05.

Results
Patient Demographics
The cohort of pediatric respiratory disease patients in this study consisted of 100 males
and 82 females. The average age of this group of patients was 8.7 years old. Patients were from
four different ethnic groups as follows: 121 white patients, 45 patients were Hispanic, 15 patients
Black and 1 patient of Asian descent [Table 1]. Asthma diagnosis was made by a combination of
family or personal history of atopy, elevated total IgE levels, positive skin or RAST test,
reversible flow limitation on spirometry, the presence of increased eosinophils, basement
membrane thickening on bronchial biopsy, or positive methacholine challenge. All asthma
patients met the definition of having severe-persistent disease that is uncontrolled, [Global
Initiative for Asthma, GINA (28, 29)]. A diagnosis of asthma was confirmed in 128 of 182
patients [70%].
5

Description

Asthma
Cohort

Non-asthma
sub-cohort

Total cohort of
patients

Number of patients
with diagnosed
disease

128

54

182

Average Age (yrs)
Age Range:
0.0-2.0

8.7

12.5

8.7

11

18

29

2.1-5.0
5.1-10.0
10.1-15.0
15.1-17.0
Gender :
M
F

27
41
33
16

13
5
13
5

40
46
46
21

68
60

32
22

100
82

85
13
30
0

36
2
15
1

121
15
45
1

95
33

31
23

126
56

Ethnicity:
White
Black
Hispanic
Asian
Medication:
Yes
No

Table 1: Cohort demographics
The cohort consisted of 182 patients [100 male and 82 females]. The average age of the entire
cohort was 8.7 years old and 128 individuals were diagnosed with asthma. For imbalances
between asthma and non-asthma for age groups, there was a significant difference in the 0-2.0
age range [Fisher’s Exact Test p=0.001], and the 5.1-10.0 age range [p=0.008]. There were
significantly more patients in the non-asthma cohort in the 0-2.0 years old age range than in the
asthma cohort. Conversely, there were significantly more asthma patients in the 5.1-10.0 year age
group than in the non-asthma cohort. No other age range, gender, ethnicity or medication use
category had significant differences between the asthma and non-asthma cohorts.
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Black patients were diagnosed with asthma more frequently [13/15], compared to other
ethnic groups in this study [Hispanic 30/45; White 85/121]. The lone Asian patient was nonasthmatic. Non-asthmatic disorders were gastroesophageal reflux disease (GERD), aspiration,
bronchitis,

bacterial

bronchitis,

structural

anomalies

(tracheomalacia,

large-airway

bronchomalacia and minor anatomic variants - accessory bronchi, tracheal bronchus, and pinhole
bronchus), chronic cough, and vascular compression – innominate artery and pulmonary artery
compression of left mainstem artery cystic fibrosis and recurrent pneumonia of unknown
etiology. Most of the diagnosed asthma patients also displayed GERD and bronchitis. There was
no significant relationship between race or gender and BAL culture positivity for the infectious
form of Chlamydia. One hundred and twenty six of the 182 patients were taking one or more
medication(s) at the time of testing including 4 patients on antibiotics [Amoxacillin, zithromax,
Trimethoprim/Sulfamethoxazole, Cefdinir and Bactrim].

Detection of Chlamydia in Bronchoalveolar Lavage Fluid
PCR was performed on the BAL samples using a 16S signature ribosomal DNA sequence
to determine the prevalence of chlamydial DNA carriage in these samples. PCR amplification of
the target sequence resulted in a 298-bp product which was identified by electrophoresis. Our
data revealed that 124 patients [68%] were positive for the presence of chlamydial DNA [see
Figure 1.A for representative agarose gel]. We previously reported on the frequency of Cp in a
similar cohort but did not specifically test all the samples for the presence of Ct (22). This
decision was mainly due to the fact that Ct is not routinely reported in association with lung
infections or pneumonitis, rather is mainly observed in sexually transmitted infection cases as
well as conjunctivitis. With strong evidence from the literature that Ct-mediated pneumonitis is
possible, especially in neonates (3, 12), all BAL samples that tested positive for chlamydial DNA
using the 16S primers we re-tested with both Cp and Ct specific primers in order to determine the
frequency

of

lung

infection

with
7

these

two

human

pathogens.

Figure 1: Representative agarose gels showing Chlamydia PCR products
(A) 16S amplified DNA from both Chlamydia-positive [1-3, 5, 6, 8-10, 11, 12, 13, 15 and 16] and
negative [4, 7, 14] BAL samples compared to the positive controls [Ct and Cp] and the negative
control [N]; L represents the DNA ladder. (B) Cp primers used to specifically amplify a 207bp
product and (C) Ct-specific primer pair amplifies an 1100bp product from the BAL fluid of
pediatric patients tested. Numbers represent individual patient samples while N and P are
negative and positive controls respectively.
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Seventy-nine [43.4%] of the 182 pediatric patient samples assayed were positive for the presence
of Cp-specific DNA, while 77 [42.3%] samples were positive for Ct-specific DNA [Figure 1B
and C]. BAL samples from 32 [17.6%] pediatric patients contained both Cp and Ct DNA.
Having recovered both Ct and Cp DNA at high rates in these BAL samples, we next
attempted to determine the proportion of these organisms that were cultivable at the time of
collection. All BAL samples were cultured on human or mouse macrophage cells using
previously published protocols (22). The results revealed that 75 [41%] of the 182 patient
samples were positive for Chlamydia when the BAL was cultured [Table 2]. Since all culture
positive samples were also PCR positive, it is clear that 60% [75/124] of all PCR positive
samples contained cultivable organisms. There was no significant difference in the finding of
infectious Chlamydia between genders; 33 of the BAL culture–positive samples were from
female patients and 42 from males. However, cultivable chlamydial organisms were found more
frequently in the asthmatic population; 59 of 128 asthmatics versus 16 of 54 non-asthmatics were
culture positive [P= 0.048 by Fishers Exact Test; see Table 2]. As an internal control, the patient
cohort was divided into inflammatory respiratory disease [N=150] and non-inflammatory airway
diseases [N=32]. The non-inflammatory respiratory disease group was categorized as such based
on normal bronchial biopsy and normal BAL. Aerobic cultures were also negative for this group
which consisted of structural defects, IgG and IgA deficiencies, aspirations and GERD; The
inflammatory group included asthma, bronchitis, and pneumonia and were also categorized based
on the bronchial biopsy, BAL and aerobic cultures. When assessed for cultivable Chlamydia, 69
[46%] of the inflammatory respiratory disease patients harbored cultivable Chlamydia versus 6
[18%] of the non-inflammatory disease group [Fisher's Exact Test (2-sided) p=0.005]. There was
no significant association between these groups and the detection of chlamydial DNA [Table
3]. Evaluation of total serum IgE levels revealed no statistically significant association between
patients with elevated serum IgE and the presence of Chlamydia DNA or cultivable organisms
[Table3].
9

Table 2: Frequency of Chlamydia in asthma versus non-asthma patient groups and
corticosteroid administration
Seventy-five of the 182 patient samples analyzed contained cultivable Chlamydia as determined
by culture techniques. Fifty-nine [46%] were from patients diagnosed with asthma; 16 [29.6%]
were from non-asthma group. * P=.048, asthma v. non-asthma (Fishers Exact test) (55). Most
patients [103/182] were being treated with corticosteroids at the time of sample collection.
Seventeen of the 21 [81%] Chlamydia-positive patients were taking a combination of inhaled and
oral steroids; 7 [31%] were taking oral steroids alone. * Represents statistically significant
associations
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Table 3: Prevalence of Chlamydia in inflammatory and non-inflammatory airway disease
When divided into inflammatory versus non-inflammatory airway disease, the majority of
patients [150] were diagnosed with various inflammation airway diseases including asthma,
pneumonia and bacterial bronchitis. The remaining 32 patients had various non-inflammatory
diseases [GERD, aspirations, laryngomalacia, dyspnea, airway and structural anomalies, chronic
cough, and vascular compression]. Cultivable Chlamydia was found more frequently in
inflammatory versus non-inflammatory airway disease [* Fisher's Exact Test (2-sided) p=0.005].
There was no significant association with PCR positive samples [p=0.531]. There was no
statistically significant association between patients with elevated serum IgE and the presence of
Chlamydia DNA or cultivable organisms.
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One hundred and three of the 182 [56.6%] patients in our pediatric cohort were taking
some form of steroid therapy at the time of BAL sample collection. Eighty two of the 128 [64%]
asthmatics in this cohort were being prescribed corticosteroids; 23 non-asthmatics diagnosed with
one or more of the other chronic respiratory diseases listed previously were also being prescribed
corticosteroids at the time of sample collection. Of the 82 asthmatic patients taking
corticosteroids, 52 [63%] were positive for the presence of chlamydial DNA and 38 tested
positive for cultivable Chlamydia in culture. Eighteen of the 23 [78%] non-asthma patients being
administered corticosteroids were also positive for chlamydial DNA; five of these were
Chlamydia culture positive. Asthma patients being prescribed both oral and inhaled
corticosteroids were more likely to harbor chlamydial DNA in their BAL fluid [17/21] than those
taking only oral [7/22, Fishers Exact Test; p=0.0461] or inhaled corticosteroids [24/39 p=0.133,
Table 2].
In addition to corticosteroids, 4 of these patients were being prescribed antibiotics at the
time of sample collection. Three of these 4 patients were diagnosed with asthma [1 patient was
diagnosed with both asthma and bronchitis] and one patient had bronchitis. The BAL from 2 of
these patients taking bactrim and TMP/SMX harbored chlamydial DNA and one was culture
positive for Chlamydia, Patients on amoxicillin and zithromax were both negative for Chlamydia.

Chlamydia, Age and Disease Associations
This cohort of 182 respiratory disease patients consisted of 128 [70%] diagnosed
asthmatics. Chlamydial DNA was recovered by PCR amplification from 86/128 [67%] patients
diagnosed with asthma [Table 2]. The remaining 41 patients were Chlamydia negative by PCR.
Chlamydial DNA was however not exclusively found in the asthma population, with 41/54 [76%]
non-asthma patient samples also PCR positive. Of the 32 patients who harbored both Ct and Cp
DNA in their lungs, 20 of 128 asthmatic and 12 of 54 were non-asthmatic. Patients in the 10.1-15
year old age-range accounted for the highest prevalence [35/46, 76%] of Chlamydia infection
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[Figure 2]. The 0-2 year old age group harbored the highest percentage of Ct DNA samples
[15/29, 51.7%]. The percentage of patient samples testing positive for Cp DNA increased from
11/29 [38%] in the 0-2 age group to 19/40 [47.5%] in the 2.1-5 age range. The number of patients
testing positive for the presence of Ct DNA decreased over time with increasing age, while the
inverse was generally true for Cp. The prevalence of both Cp and Ct decreased after age 15
[Figure 2].

BAL Cellularity and Chlamydia
Bronchial lavage fluid collected from each patient was analyzed in a clinical setting for
the presence of various cell types. Specifically, cell counts were performed to determine the
number of lipid laden macrophages (LLM)/monocytes, eosinophils, lymphocytes and neutrophils.
Forty five patient samples showed elevated levels of eosinophils, [Table 4], 149 contained
lymphocytes, and monocytes were found in 89 patient samples. There was no significant
difference in percentages of alveolar macrophages, lymphocytes, and monocytes in the asthma
versus non-asthma group. The mean cell counts for monocytes, eosinophils, lymphocytes and
neutrophils are presented for Chlamydia positive vs. negative samples [DNA and culture] and
asthma vs. non-asthma sub-cohorts [Table 4]. The mean eosinophil count was statistically higher
in asthmatics [5.5%] vs. non-asthmatics [0.06%, Fisher’s Exact Test p=0.001]. The range of BAL
eosinophil counts in asthmatic patients was from 1-25%. The mean neutrophil count in
Chlamydia culture positive patients was 68.39% compared to 30.87% in culture negative subjects
[Fisher’s Exact Test, two-tailed; p=0.001]. Since this group of children all had severe respiratory
diseases and many had GERD, it was not surprising to discover that 175 of the 182 BAL samples
contained at least some LLM. The cytological evaluation did not reveal a statistically significant
association between the finding of LLM and Chlamydia organisms. There were few LLM [1-3
LLM per field], in 14 patients, moderate [4-6 LLM per field] amounts in 66 patients and many
[≥6 LLM per field] in 95 patients. Sixty eight of 75 culture-positive, versus 93 of 107 culture
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Figure 2: Age-based prevalence of chlamydial DNA in BAL fluid
The correlation between age and the prevalence of Cp and Ct organisms determined by PCR
analysis is shown. Note that patients in the 10.1-15 year age range accounted for the highest
percentage [35%] of total Chlamydia organisms. The 0-2 year age group harbored the highest
percentage of Ct organisms [15/29, 51%].
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Table 4: BAL cellularity and the presence of Chlamydia
The bronchial lavage fluid of each patient was assessed for the presence of various cell types. The
table outlines the presence of these cells and assesses their correlation with cultivable Chlamydia,
chlamydial DNA and diagnosis of asthma. The mean eosinophil count was statistically higher in
asthmatics compared to non-asthmatics [Fishers Exact Test p=0.001]. The mean neutrophil count
was significantly increased in Chlamydia culture positive patients over culture negative ones
[68.39% vs. 30.87% respectively; Fishers Exact Test-two-tailed p=0.001]. There was no
statistically significant correlation between any of the other cell types and Chlamydia organism,
DNA or disease association. * Represents statistically significant associations
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negative patient samples displayed moderate to many LLM [Table 4].
Discussion
Chronic lung disease affects an increasingly wide cross-section of the world’s population,
manifesting itself mainly as asthma, COPD, pneumonia and bronchitis (2, 18). Globally,
respiratory infections in childhood are a leading cause of disease and substantially contribute to
school absenteeism and severe economic strain on healthcare resources (30). In the developing
world, respiratory infections are also a major cause of childhood mortality (31). Respiratory
diseases of infancy and childhood are predominantly infectious in nature and can be caused by
either viruses, bacteria or parasites (32).
In the current observational study we demonstrate that human strains of Chlamydia, Ct
and Cp, can be isolated from the lungs of children with chronic respiratory disease. Cp has long
been reported as an etiologic agent of community acquired pneumonia and has been found in high
prevalence in the lungs of adults (33), and also in the respiratory secretions of adult asthmatics,
and lungs of COPD patients (34). Recently, we reported that Cp can also infect the lung tissue of
children and might contribute to the pathology commonly seen in a variety of chronic respiratory
diseases (22). While the number of patients with chlamydial DNA in their lower respiratory tract
analyzed in this study is surprisingly high, compared to those in some recent studies (35, 36), our
cohort is significantly larger. Furthermore, the type of samples collected by us differs from most
published work to date which utilize samples from the upper respiratory tract. It is also
noteworthy that our cohort is a select group of severely ill children with chronic respiratory
disease and as such, may not be reflective of the general population. Most other studies that report
a prevalence of Cp in the 5-30% range assess sputum, nasal aspirates or throat swab samples (35,
37, 38) as opposed to bronchial washings, a more invasive procedure with which our samples
were obtained. In a 2001 study where Cp PCR was performed on tracheobronchial aspirate the
authors reported a 51.9% prevalence (39). It should again be noted that the samples we used were
residual in nature and not obtained for the purpose of research, but as a part of the diagnostic
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evaluation of each patient. Importantly, most studies by others only tested for the presence of Cp
DNA, while the presence of both Cp and Ct DNA was assayed for in this study.
The data revealed a significant association between cultivable Chlamydia and asthma
diagnosis, consistent with our earlier findings. Importantly, the data also confirm that at earlier
ages of life, Ct appears more prevalent than Cp in BAL samples. Although the organisms were
also found in the neonate to two years old age group, it is not until age 5 to10 years old that an
increased prevalence of Cp is observed. This suggests that these later infections may have been
contracted through increased social interactions, possibly in pre-school or daycare settings. These
findings agree with previously published data suggesting that Ct can be found in the lower
respiratory tract of newborns and can lead to pneumonitis (12, 15, 21). Evidence for the presence
of Cp in the human placental tissue also exists (40-42). This suggests a potential role for
intrauterine Ct infection in the development of chronic respiratory disease in infants.
Increased lipid content in alveolar macrophages of bronchoalveolar lavage fluid is
thought to be a useful indicator for recurrent pulmonary aspiration (43, 44). Previous studies have
confirmed that Chlamydia has the ability to survive and even thrive in alveolar macrophages (45,
46). It has been previously reported that Cp induces foam cell formation by human monocytederived macrophages (47). Exposure of macrophages to Cp followed by the addition of lowdensity lipoprotein [LDL] in tissue culture, caused a marked increase in the number of foam cells
and accumulation of cholesteryl esters (47). These data therefore suggest that an infectious agent
can induce macrophage foam cell formation and implicate Cp as a causative factor in
inflammatory diseases associated with foam cell formation, including atherosclerosis. While not
statistically significant, we observed a correlation between the finding of moderate to many LLM
[greater than 4 cells per high power field] and Chlamydia-positivity by PCR and culture.
Infection of macrophages by Chlamydia, coupled with epithelial cell damage in the airways could
increase the inflammatory response in the lungs. With increased oxidative bursts by these
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phagocytes and the release of proinflammatory cytokines such as TNF-α, IL-1β, IL-6 and IL-8,
airway hyperreactivity and pulmonary inflammation might be significantly increased.
In the current study, asthma patients treated with a combination of oral and inhaled
corticosteroids were more likely to harbor chlamydial DNA [Table 4]. Inhaled glucocorticoids are
a mainstay of asthma therapy. Oral steroid treatment is the most potent therapeutic intervention
available for the effective relief of symptoms in acute and chronic asthma, especially for patients
with severe disease. However, corticosteroids negatively affect many aspects of cell-mediated
immunity and favor the shift from a T-helper-1-type response towards a T-helper-2-type
response. Corticosteroids may thus severely impact the host's ability to eradicate an intracellular
pathogen, such as Chlamydia, which requires properly functioning cell-mediated [T-helper-1type] immune responses for pathogen clearance. Previous in-vitro studies confirm that persistent
Chlamydia in macrophages are reactivated when corticosteroid treatment is administered,
resulting in the release of infectious elementary bodies (EB) particles into the immediate
surroundings whereby new cells are infected (48, 49). Corticosteroids have also been shown to
reactivate persistent Chlamydia carriage leading to an active growth phase, thus, increasing the
production of pro-inflammatory cytokines at the site of infection and further amplifying
inflammation in the airways of patients with asthma (50-53). The combination of both inhaled
and oral steroid treatment might represent an increased amount of corticosteroids in the
circulation leading to increased reactivation of Chlamydia.
Along with previously published studies, the work reported here suggests that further in
depth investigations of the involvement of the Chlamydiaceae family of obligate intracellular
pathogens in the etiology and exacerbation of asthma and other chronic respiratory diseases,
particularly in pediatric populations are needed. The current data confirms the presence of both
Cp and Ct organisms in the lungs of these patients. Importantly, patients with asthma and other
inflammatory airway disease were more likely to harbor cultivable chlamydial organisms in their
lower respiratory tract.
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CHAPTER 2
INFECTIOUS CHLAMYDIA PNEUMONIAE IS ASSOCIATED WITH ELEVATED IL-8
AND AIRWAY NEUTROPHILIA IN CHILDREN WITH REFRACTORY ASTHMA
Abstract
Background: Neutrophilic asthma is thought to be less responsive than eosinophilic asthma to
anti-inflammatory therapies including corticosteroids. Chlamydia pneumoniae has been
implicated in asthma, possibly by induction of IL-8. We hypothesized that IL-8 is increased in the
bronchoalveolar lavage (BAL) fluid from children with asthma and C. pneumoniae.
Methods: BAL fluid was analyzed for C. pneumoniae and IL-8 using PCR and ELISA from 2
asthma patient populations Bronx, NY and Massachusetts with an average age of 8 and 8.7 years
old, respectively. For comparison, samples were also analyzed for C. trachomatis and
Mycoplasma 16S DNA.
Results: Of 18 Bronx samples analyzed, 6 (33%) were PCR-positive for C. pneumoniae, 10
(56%) for C. trachomatis and 8 (44%) for Mycoplasma 16s DNA. IL-8 from C. pneumoniaepositive samples was 3.3-fold higher compared with negative samples (p= 0.003). There was no
difference between patients tested for C. trachomatis or Mycoplasma. Of 84 Massachusetts
samples analyzed, 42 (50%) were PCR-positive for C. pneumoniae, 42 (50%) for C. trachomatis
and 13 (16%) for Mycoplasma. IL-8 concentration from C. pneumoniae-positive samples was
10.49-fold higher compared with negative samples (p= 0.0001). As in the Bronx cohort, there
were no differences between patients tested for C. trachomatis or Mycoplasma. Lastly, BAL
neutrophilia predicted the presence of C. pneumoniae but not Mycoplasma or C. trachomatis.
Conclusions: Children with asthma who were PCR-positive for C. pneumoniae demonstrated
elevated levels of IL-8 and neutrophils in BAL fluid compared to similar patients who were
positive for C. trachomatis or Mycoplasma organisms, but PCR-negative for C. pneumoniae.
Undiagnosed C. pneumoniae infection in children may therefore contribute to poorly controlled
asthma via induction of IL-8.
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Introduction
There is increasing evidence that inflammatory phenotype in asthma partly dictates both severity
of disease and response to therapy (1, 2). For example, patients with neutrophilic asthma, as
measured by induced sputum or bronchoalveolar lavage (BAL) fluid, tend to be less responsive to
traditional asthma medications including inhaled and oral corticosteroids (3-5). Although the
precise mechanism for these observations is currently unclear, some postulate that undiagnosed
chronic bacterial infection may contribute to this phenomenon by induction of specific
proinflammatory cytokines including IL-8, a potent neutrophil chemoattractant and activating
factor (6). IL-8 is known to be released by monocytes (7), macrophages (8), fibroblasts (8), and
airway epithelial cells (9). Increased levels of IL-8 have been described in chronic neutrophilic
airway inflammation in patients with refractory asthma, cystic fibrosis and other chronic airway
diseases (4, 10-12). Although acute exposures to airway irritants, including particulate matter,
viruses and endotoxin have been shown to induce production of IL-8, it is unclear whether
chronic, undiagnosed infections can lead to a sustained increase in this inflammatory cytokine,
and thus contribute to ongoing disease (13).
Chlamydia pneumoniae, an obligate intracellular bacterium, has also been implicated in
poorly controlled asthma (14, 15). In addition, past investigations have demonstrated that C.
pneumoniae can enhance IL-8 secretion (16), and that this secretion may be initiated by
adherence of the organism to human airway epithelial cells (17). Importantly, confirmation of
infection can be difficult, and thus true prevalence of infection is unknown. As such, the specific
role for C. pneumoniae in chronic respiratory diseases including asthma is also unclear (18).
In previous investigations, we utilized modified culture techniques and molecular methods to
demonstrate a high prevalence of C. pneumoniae in BAL fluid from children with asthma (14,
15). It is unclear from these past studies whether the presence of C. pneumoniae alters the
cytokine profile in the airway of such patients. Thus, we sought to determine whether C.
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pneumoniae was associated with IL-8 levels in BAL fluid from children with poorly controlled
asthma. Portions of this manuscript were presented as a poster presentation at the 2009 ATS
International Meeting (19).

Materials & Methods
Sample Collection
We obtained banked BAL samples that were collected from patients undergoing flexible
bronchoscopy with lavage under a separate IRB-approved protocol. We specifically sought to
identify samples collected from patients with poorly controlled asthma and no other identifiable
pathology contributing to their persistent symptoms. BAL was performed according to the normal
protocol for our institution and as previously reported (14, 15). Briefly, the right middle lobe or
lingula was lavaged with a total of 3cc/kg of normal saline divided into 3 equal aliquots
(maximum aliquot of 20cc). If a patient required lavage in a separate lobe for clinical purposes
(i.e. recurrent pneumonia in a different lobe), the sample obtained at that time was utilized.
Additional lavage was not performed for investigational purposes. Up to 5cc of recovered fluid
was immediately frozen and stored in –80°C until analysis.

PCR Analysis
Genomic DNA was isolated from BAL using the QIAMP DNA Blood mini kit (Qiagen).
Polymerase chain reaction (PCR) was used to detect both Chlamydia and Mycoplasma DNA. We
used the following primer sets to determine the presence and prevalence of C. pneumoniae and C.
trachomatis respectively: Cpn201 and 202 primers (product 207 bp) and Ct using primers Ct
sense and Ct anti-sense (504 bp). The PCR products were then separated by electrophoresis on
2% agarose gels and visualized by staining with ethidium bromide. Mycoplasma 16S was
performed using commercial kits (Maxim Biotech, Inc. Mycoplasma 16S rRNA kit-SP-10521 and
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PCR Primer Amplification Kit, Mycoplasma pneumoniae, Attachment Protein P1; SP-10523)
according to the manufacturers guidelines.

Performing IL-8 ELISA
Immediately following bronchoscopy, BAL samples were processed and stored at -80°C until
analysis. Concentration of IL-8 was determined in BAL fluid using BD OptEIA Human-IL-8
ELISA Kit II (BD Biosciences, San Jose, California) according to the manufacturer’s
instructions. Briefly, the ELISA test used was a solid phase sandwich ELISA (Enzyme-Linked
Immunosorbent Assay) which uses a monoclonal antibody specific for IL-8 coated on a 96-well
plate. Standards and 100ul of undiluted BAL fluid samples were added to the wells. The wells
were washed and streptavidin-horseradish peroxidase conjugate mixed with biotinylated antihuman IL-8 antibody was added. Wells were subsequently washed again and TMB substrate
solution was added, producing a blue color which is in direct proportion to the amount of IL-8
present per sample. The Stop Solution was then added, changing the color to yellow, and the
microwell absorbances were then read at 450 nm.

Cell Counts
BAL cell counts and differentials were performed according to standard techniques in the
hospital’s Hematology Clinical Laboratory at Baystate Medical Center (Springfield, MA) and
Children's Hospital at Montefiore, Albert Einstein College of Medicine (Bronx, NY) as
previously reported (14). Briefly, cell enumeration was performed manually using a cell counting
chamber under phase microscopy with results expressed as “number of cells per cubic
millimeter”.

BAL

differential

counts

were

performed

using

Wright

stained

cytospin preparations of BAL which were then examined under oil-immersion microscopy (50X
or 100X). Results were expressed on the basis of a 100 cell count survey.
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Statistical Analysis
All statistical analyses for IL-8 concentration among the different groups of the patient population
were performed using Microsoft Excel®. Statistical associations were determined with Fisher's
exact test and Chi-square with Yates correction (SPSS 15.0 software). A p-value of 0.05 was
considered significant and all tests were two-tailed. Sensitivity, specificity, positive predictive
value and negative predictive values were performed using the Clinical Calculator1 online
program at http://faculty.vassar.edu/lowry/VassarStats.html.

Results
Bronx patients
Of 31 BAL samples collected and banked between July 2007 and July 2008, 20 were
obtained from patients with poorly controlled asthma and no identifiable airway pathology
contributing to persistent respiratory symptoms. Of these 20 patients, 2 were excluded from
analysis because their asthma was complicated by allergic bronchopulmonary aspergillosis. Thus,
a total of 18 samples were analyzed (12 males and 6 females). All patients included in the study
were diagnosed with moderate to severe persistent asthma that was under poor control, as defined
by the current NIH guidelines(20). All were chronically treated with high dose inhaled
corticosteroids, although 2 patients self-discontinued these medications prior to bronchoscopy.
With the exception of one child, all patients in this cohort were also receiving or had previously
been managed with additional therapies including leukotriene receptor antagonists (LTRA) and/or
long-acting beta agonists (LABA). 2 patients were receiving omalizumab (Table 5).
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BRONX

C. pneumoniae

C. trachomatis

Mycoplasma

Positive (%)

Positive (%)

Positive (%)

(n=6)

(n=10)

(n=8)

9.0

10.0

10.3

Male

4 (66.7%)

6 (60.0%)

5 (62.5%)

Female

2 (33.3%)

4 (40.0%)

3 (37.5%)

Black

1(17%)

6 (60%)

2 (25%)

Hispanic

5 (83%)

4 (40%)

6 (75%)

6 (100.0%)

10 (100.0%)

8 (100.0%)

Inhaled steroids

6 (100.0%)

6 (60.0%)

4 (50.0%)

Oral steroids

2 (33.3%)

1 (10.0%

1 (12.5%)

Other*

4 (66.7%)

3 (30.0%)

3 (37.5%)

Age (yr)
Gender

Race

Asthma
Medication

Table 5: Characteristics of Bronx NY, Study Population
The Bronx patient cohort consisted of 18 patients, 12males and 6 females undergoing diagnostic
bronchoscopy. All patients were being prescribed high dose corticosteroid treatment at the time of
sample collection. Indeed several patients in this cohort had previously been managed with longacting beta agonists (LABA). Medications at the time of sample collection consisted mainly of
inhaled corticosteroids, leukotriene receptor antagonist and long-acting beta agonists (LABA).
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Massachusetts patients
We previously analyzed C. pneumoniae, C. trachomatis and Mycoplasma status in a
large cohort of patients undergoing clinically indicated bronchoscopy in Massachusetts (14, 15).
Because of the initial results obtained from our smaller Bronx cohort, we reviewed data from a
select sub-cohort of these samples in order to identify similar patients who underwent
bronchoscopy because of poorly controlled asthma and no alternate diagnosis for persistent
symptoms. For comparison we also tested 7 samples from patients with culture-documented
bacterial bronchitis and asthma. We identified 84 patients who underwent flexible bronchoscopy
with lavage for poorly-controlled asthma and no other diagnosis to explain persistent respiratory
symptoms. At the time of bronchoscopy, all were being prescribed high doses of inhaled
corticosteroids, and all were either receiving or had not responded to adjunct therapies including
LABA, LTRA, omalizumab or anti-reflux medications (Table 6).

IL-8 concentration and C. pneumoniae in Bronx patients
Of the 18 Bronx samples analyzed, 6 (33%) were PCR-positive for C. pneumoniae. IL-8
concentrations from C. pneumoniae-positive samples were 3.3-fold higher on average compared
with C. pneumoniae-negative samples (Figure 1A; 167.0 ± 56 pg/ml vs. 51.0 ± 60 pg/ml,
respectively; p = 0.0003). In comparison, 10 samples (56%) were PCR-positive for C.
trachomatis and 8 (44%) were positive for Mycoplasma. When IL-8 was analyzed in relation to
C. trachomatis and Mycoplasma positivity, no differences were observed between DNA positive
and negative samples (79.5 ± 81 pg/ml vs. 102.4 ± 82 pg/ml, and 101.0 ± 74 pg/ml vs. 114.2 ± 88
pg/ml, respectively; Figures 3B and 3C).
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Massachusetts

C. pneumoniae

C. pneumoniae

Positive (%)

Negative (%)

(n=42)

(n=42)

8.1

7.8

8.0

Male

25 (59.5%)

21 (50.0%)

46

Female

17 (40.5%)

21 (50.0%)

38

Caucasian

25 (59.5%)

29 (69.1%)

54

Black

6 (14.3%)

4 (9.5%)

10

Hispanic

11 (26.2%)

9 (21.4%)

20

Positive

32 (76.2%)

25 (59.5%)

57

Negative

4 (9.5%)

11 (26.2%)

15

Not Done

6 (14.3%)

6 (14.3%)

12

42 (100.0%)

42 (100.0%)

84

Inhaled steroids

23 (54.8%)

20 (47.6%)

43

Oral steroids

10 (23.8%)

9 (21.4%)

19

Other*

19 (45.2%)

21 (50.0%)

40

Age (yr)
Gender

Total

Race

BMTH

Asthma
Medication

Table 6: Characteristics of Study Population in Massachusetts Cohort
This cohort consists of patients mainly from western Massachusetts. There were 120 patients with
an average age of 8 years old and like the Bronx cohort presented with chronic, severe,
respiratory disease and prescribed high doses of corticosteroids. Seventy four of these patients
were asthmatics and IL-8 positivity had a significant correlation with basement membrane
thickening based on biopsy taken during bronchoscopy. There were no significant correlations
between IL-8 positivity and age, gender or race. *This includes acid reflux and other asthma
medications.
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Figure 3: Elevated IL-8 in the BAL of C. pneumoniae positive Bronx Patients.
We analyzed18 samples in our Bronx cohort and 6 (33%) were PCR positive for C. pneumoniae.
C. pneumoniae-positive patient samples had an IL-8 concentration that was 3.3 fold higher on
average compared with C. pneumoniae-negative samples, p = 0.0003 (graph A). When similarly
analyzed, C. trachomatis and Mycoplasma-positive samples did not demonstrate significant
differences, compared to negative samples (graphs B and C respectively). Dark horizontal line
represents the mean concentration for each group and symbols represent individual patient
samples in the positive or negative column. P-values are indicated for each set of positive and
negative group.
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IL-8 concentration and C. pneumoniae in Massachusetts patients
Similar, but more striking results were seen in the Massachusetts patients. Of the 84
samples analyzed 42 (50%) were PCR-positive for C. pneumoniae (note that 21 of the 42 samples
were positive for both C. pneumoniae and C. trachomatis). IL-8 concentration from C.
pneumoniae-positive samples was 10.49-fold higher on average compared with C. pneumoniaenegative patient samples (Figure 2A; 129.0 ± 65 pg/ml vs. 12.3 ± 28 pg respectively, p = 0.0001).
There was no difference in gender distribution, age or medications being prescribed at the time of
sample collection between C. pneumoniae PCR-positive and negative patients (Table 2). In
comparison, 42 samples (50%) were positive for C. trachomatis and 13 (16%) were positive for
Mycoplasma. As in the Bronx cohort, there were no significant differences in IL-8 levels between
DNA positive and negative samples patients tested for C. trachomatis or Mycoplasma (76.0 ± 79
pg/ml vs. 73.6 ± 79 pg/ml and 60.7 ± 51 pg/ml vs. 66.5 ± 73 pg/ml, respectively; Figure 4B and
4C).
Because PCR positivity may not equate with viability of organisms, we reviewed
previous culture data for the Massachusetts patients (14, 15). Consistent with the PCR data from
both the Bronx and Massachusetts cohorts, we found that culture-positive samples demonstrated a
9.85-fold increase in IL-8 levels compared to culture-negative samples (Figure 5; 113.3 ± 69
pg/ml vs. 11.5 ± 30 pg/ml, respectively; p = 0.0001).
Lastly, to determine whether there were differences in IL-8 levels between C.
pneumoniae and other common bacterial pathogens, we tested 7 asthmatic patients within our
cohort, that were also diagnosed as bacterial bronchitis patients, with one or more of the
following microbes in their BAL fluid: Moraxella catarrhalis, Haemophilus influenzae,
Pseudomonas aeruginosa, Neisseria species and Streptococcus pneumoniae. Interestingly, IL-8
levels in the asthmatic patients were 2.0 fold higher when compared to those of the bacterial
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Figure 4: Elevated IL-8 in the BAL of C. pneumoniae positive Massachusetts Patients
There was an average of 10.75 fold higher IL-8 concentration in the BAL of C. pneumonia
positive patients compared to C. pneumoniae-negative ones (129.0 ± 65 pg/ml versus 11.8 ± 28
pg/ml respectively, p = 0.0001; graph A). When we assessed the IL-8 concentrations for samples
positive for C. trachomatis and Mycoplasma DNA there was no significant difference (77.5± 74
pg/ml vs. 75.9 ± 78 pg/ml, and 60.7 ± 51 pg/ml vs. 66.9 ± 68 pg/ml; graph 2B and 2C,
respectively).
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Figure 5: Elevated IL-8 is strongly associated with cultivable Chlamydia
Forty five of 51(88.2%) IL-8 positive samples were Chlamydia culture-positive confirming that
there was possibly an active infection ongoing at the time of sample collection. The culture
positive group had average IL-8 levels of 113.5 ± 73 pg/ml vs. 11.5 ± 30 pg/ml for culture
negative samples (p=0.0001, Fisher exact T-test).
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Bronchitis/asthma patient sub-cohort described above (86.1 ± 74 vs. 42.9 ± 50, p = 0.0001; Figure
6).

When

C.

pneumoniae-positive

asthmatic

patients

were

compared

to

bacterial

bronchitis/asthma patients who were also positive for C. pneumoniae, we found a 2.87-fold in IL8 levels for the asthmatic patients (129.3 ± 62 vs. 45.0 ± 56, Figure 6) this difference was also
statistically significant (p= 0.0001).

BAL Neutrophilia Predict C. pneumoniae Infection
Because we found an association between C. pneumoniae status and IL-8 levels in both
patient populations, and since the molecular and modified culture techniques utilized in our study
may not be readily available in the clinical setting, we then sought to determine whether BAL
neutrophilia could predict the presence of C. pneumoniae. Because of the limited number of
samples collected from Bronx patients, we were unable to draw any reliable conclusions in this
patient population. Bronchial neutrophilia (>10% of neutrophils) in the Massachusetts patient
cohort, however was significantly associated with the presence of C. pneumoniae DNA (Fisher's
exact test, two-tailed P–value = 0.0001). The overall sensitivity, specificity, positive predictive
value (PPV), and negative predictive value (NPV) of >10% BAL neutrophils/ml to predict C.
pneumoniae infection were 93%, 76%, 80% and 92%, respectively (Table 7). Neither C.
trachomatis nor Mycoplasma DNA was a strong predictor of airway neutrophilia with sensitivity
of 55% and 53%; specificity 38% and 40%; PPV 46% and 14%; NPV 45% and 82% respectively.
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Figure 6: Asthmatic patients with C. pneumoniae have higher IL-8 levels than bacterial
bronchitis patients
Seven patients tested were diagnosed with bacterial bronchitis. The averageIL-8 level in our
asthma patients was 73.7 pg/ml while the average level in the bronchitis patients was 27.1 pg/ml
(P=0.0108). The data also shows that while not statistically significant, asthma patients who were
C. pneumoniae positive had a 3.6 fold higher IL-8 level compared to C. pneumoniae positive
bronchitis patients.
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Elevated Neutrophils
Non-Neutrophilic
Subtotals

Cp Positive

CP Negative

Subtotals

69 (30.6%)
18 (8%)
42

10 (11.9%)
32 (38.1%)
42

49
35

Table 7: Elevated neutrophil counts predict C. pneumoniae infection.
The presence of the C. pneumoniae DNA by PCR was assessed to determine its association with
elevated BAL neutrophil counts. *C. pneumoniae (Cp) positivity was statistically significant
(Fisher's exact test, P= 0.0001) in patients with elevated neutrophil counts (>10%) compared to
neutrophil negative patients (<10%).
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Discussion
Patients with poorly-controlled asthma have persistent symptoms despite treatment with
inhaled corticosteroids and other adjunct therapies including LABA and LTRA (20, 21). While
the majority of patients with asthma demonstrate enhanced allergic inflammatory responses, some
patients with poorly-controlled disease exhibit a non-allergic, TH1-dominant inflammatory
phenotype that may be less responsive to traditional anti-inflammatory therapy (3-5). Currently,
the mechanisms underlying different inflammatory phenotypes in asthma are unknown. Similarly,
the clinical relevance and potential implications of a non-allergic inflammatory phenotype in
asthma are not clear. In the present study, we utilized a convenience sample of patients with
poorly-controlled asthma who underwent flexible bronchoscopy and found that BAL fluid from
patients that were DNA positive for C. pneumoniae demonstrated elevated IL-8 levels compared
to patients who were negative for C. pneumoniae. This finding was even more significant for
patients with culture-positive BAL (Massachusetts cohort). Importantly, none of these patients
was suspected of having C. pneumoniae in their lower respiratory secretions by clinical measures
(i.e. active pneumonia). Because this pattern was seen in 2 distinct patient populations but did not
hold true for C. trachomatis or Mycoplasma, it seems less likely that this association simply
reflects a generalized response to airway colonization with atypical bacteria, but rather a response
to C. pneumoniae. As such, it seems plausible that C. pneumoniae may represent a sub-phenotype
of poorly-controlled asthma that is associated with a non-allergic (i.e. IL-8-associated)
inflammatory response. We also demonstrated that airway neutrophilia may be an indicator for C.
pneumoniae infection, particularly when conventional cultures fail to identify other bacterial
organisms in the lower airway. Because IL-8 is a known neutrophil chemotactic factor, and since
C. pneumoniae is known to induce IL-8 (22, 23), the association with neutrophilia may not seem
overly surprising. However, because the molecular and modified culture techniques utilized to
identify C. pneumoniae in our investigation may not be readily available in the clinical setting,
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BAL fluid cell counts may become a useful screening tool during evaluation of poorly-controlled
asthma.
There are important limitations to our investigation that should be noted. Because we
obtained samples from a convenient population of poorly-controlled asthmatics who underwent
flexible bronchoscopy, our results may not be applicable to the majority of patients whose disease
is easily controlled with intermittent use of beta agonists or low dose inhaled corticosteroids.
Indeed, regular utilization of an invasive procedure (bronchoscopy) seems unwarranted for such
patients. Nevertheless, our findings may be important for the minority of patients whose
symptoms remain poorly-controlled despite standard treatment. Current recommendations for
such patients focus on escalation of existing therapy and identification of co-morbid conditions
including gastroesophageal reflux, allergic disorders, sinusitis or obstructive sleep apnea (21). C.
pneumoniae may represent an additional co-morbid condition that is under diagnosed, and
importantly, one for which additional adjunct therapies could potentially be designed. An
additional limitation to our study is that we were unable to analyze true control samples (for
example, children with no respiratory disease who are undergoing elective surgery), which has
been a common limitation in similar pediatric BAL studies (24-26). Nevertheless, an important
underlying objective of our study was to characterize a potential sub-phenotype of poorlycontrolled asthma, namely that associated with C. pneumoniae. As such, our control group
consists of patients with poorly-controlled asthma who do not demonstrate evidence of C.
pneumoniae in the lower airway. Although we acknowledge that analysis of true controls could
enhance our findings, our results demonstrating different inflammatory phenotypes between C.
pneumoniae-positive and negative patients should not be overlooked.
Our findings may have future implications in the diagnosis and treatment of children with
poorly-controlled asthma. Because macrolide therapy is widely employed in the clinical setting
for community acquired pneumonia and other respiratory illnesses including sinusitis, and since
prolonged courses of macrolide antibiotics are increasingly utilized in chronic inflammatory
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diseases such as cystic fibrosis, its efficacy and safety profiles are well documented(27, 28). From
the current investigation, it is unclear whether patients with poorly-controlled asthma who are
also harboring C. pneumoniae would benefit from the addition of macrolide antibiotics. However,
a previous investigation in adults utilized clarithromycin as an adjunct treatment for refractory
asthma, documenting a reduction of IL-8 levels during treatment as well as clinical benefits that
were most dramatic for patients with neutrophil-predominant asthma (as opposed to
allergic/eosinophilic disease) (29). In this study, the mechanism of action was presumed to
involve the anti-inflammatory properties of macrolides. However, given our current work, there is
a possibility that some of these patients, particularly those with neutrophil-predominant
inflammation, were unknowingly infected with C. pneumoniae. A similar large-scale
investigation in pediatric patients demonstrated no benefit of azithromycin for children with
moderate-to-severe persistent asthma (30). Unlike the previous study in adults, however, these
investigators did not perform analysis based on inflammatory phenotype, and only upper airway
secretions were tested for the presence of C. pneumoniae. It has been documented that C.
pneumoniae preferentially colonizes the lower airways (31, 32). Lastly, it should be noted that C.
pneumoniae has a propensity to cause chronic or latent infections that may not be adequately
treated with standard courses of therapy used for community-acquired pneumonia or bacterial
sinusitis (33, 34). In such cases, prolonged courses of therapy may be required.
Based on our current work and the previous work of others, we propose additional
investigations focusing on the evaluation and management of children with poorly-controlled
asthma which include analysis of inflammatory phenotype and, based on the observed phenotype,
further analysis for the presence of C. pneumoniae in the lower respiratory tract.
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CHAPTER 3
THE PREVALENCE AND IDENTITY OF CHLAMYDIA-SPECIFIC IgE IN CHILDREN
WITH ASTHMA AND OTHER CHRONIC RESPIRATORY SYMPTOMS
Abstract
Background: Recent studies have confirmed the presence of viable Chlamydia in the
bronchoalveolar lavage (BAL) fluid of pediatric patients with airway hyperresponsiveness. While
specific IgG and IgM responses to C. pneumoniae are well described, the response and potential
contribution of Ag-specific IgE are not known. The current study sought to determine if infection
with Chlamydia triggers the production of pathogen-specific IgE in children with chronic
respiratory diseases which might contribute to inflammation and pathology.
Methods: We obtained BAL fluid and serum from pediatric respiratory disease patients who
were generally unresponsive to corticosteroid treatment as well as sera from age-matched control
patients who saw their doctor for wellness checkups. Chlamydia-specific IgE was isolated from
BAL and serum samples and their specificity determined by Western blot techniques. The
presence of Chlamydia was confirmed by species-specific PCR and BAL culture assays.
Results: Chlamydial DNA was detected in the BAL fluid of 134/197 (68%) patients. Total IgE
increased with age until 15 years old and then decreased. Chlamydia-specific IgE was detected in
the serum and/or BAL of 107/197 (54%) patients suffering from chronic respiratory disease, but
in none of the 35 healthy control sera (p<0.0001). Of the 74 BAL culture-positive patients, 68
(91.9%, p=0.0001) tested positive for Chlamydia-specific IgE. Asthmatic patients had
significantly higher IgE levels compared to non-asthmatics (p=0.0001). Patients who were
positive for Chlamydia DNA or culture had significantly higher levels of serum IgE compared to
negative patients (p=0.0071 and p=0.0001 respectively). Only 6 chlamydial antigens induced
Chlamydia-specific IgE and patients with C. pneumoniae-specific IgE had significantly greater
levels of total IgE compared to C. pneumoniae-specific IgE negative ones (p=0.0001).
Conclusions: IgE antibodies play a central role in allergic inflammation; therefore production of
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Chlamydia-specific IgE may prove significant in the exacerbation of chronic, allergic airway
diseases, thus highlighting a direct role for Chlamydia in asthma pathogenesis.

Introduction
Inflammation of the airways is the most common finding in all asthma patients and today,
most asthma experts consider airway inflammation a central feature of asthma pathogenesis (1,
2). The genetic predisposition to asthma development has been well recognized and the IgEmediated response to common aero-allergens represents the most common form of the disease in
childhood and early adulthood (3). Published evidence strongly suggests a relationship between
microbes and asthma (4). It has long been known that the most potent triggers of wheezing are
mediated by viruses, however, we do not understand the mechanisms involved in how they
contribute to disease onset and progression. Even less is known about the relationship between
asthma and bacteria. Recent studies confirm that bacterial respiratory infections are frequently
associated with increased airway obstruction in patients with bronchial asthma (3). While the
hygiene hypothesis predicts that infections in early life by non-pathogenic microbes should
protect against asthma and atopy (5), there is increasing evidence that certain chronic pathogenic
infections might also promote airway hyperresponsiveness and asthma development or
exacerbation (6-8).
Approximately 20% of wheezing children have serological evidence of an immune
response to Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarralis (9,
10). More recently, Mycoplasma pneumoniae and Chlamydia pneumoniae have been identified in
5–25% of children with asthma exacerbations (11-13). Hahn et al also reported a significant
improvement in overall asthma symptoms at treatment completion which persisted for 3 months
despite withdrawal of azithromycin in an adult population (14, 15).
Earlier studies by Welliver et al. (16) reported IgE responses to RSV in children with
bronchiolitis and showed that this IgE response was related to recurrent wheeze, but not to lung
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function and allergic sensitization at an early age. This suggests that IgE antibodies to RSV occur
independently of atopy and may be indicative of an ongoing asthmatic process. Specific IgE
to bacterial colonizers has also been reported. H. influenzae and S. pneumoniae specific IgE
antibodies have been found in the serum of approximately a third of atopic children and asthmatic
adults, however, they were all related to a subject's atopic status (17). The implication here is that
IgE has a complex relationship with asthma that might not be dependent on the specific allergens
that are routinely assayed for (18).
In the current study we examined the BAL fluid and serum of a large cohort of children
with chronic respiratory disease for the presence of Chlamydia-specific IgE antibodies. We
hypothesize here that the presence of Chlamydia-specific IgE antibodies explains, at least in part,
the mechanism of chlamydial involvement in either initiating or exacerbating chronic allergic
airway disease.

Materials & Methods
Patients and Samples
Serum and BAL samples were analyzed from 197 patients between the ages of 0-20 who were
patients at Baystate Medical Center. BAL samples were originally obtained from patients for
diagnostic or treatment purposes. Children were considered for bronchoscopy only after a
thorough, non-invasive evaluation did not yield a definitive diagnosis; symptoms were not
improving with time; aggressive medical management had not been successful and the child was
truly compromised i.e., was missing school, could not participate in physical activity and had
frequent symptoms. Airway reactivity was monitored by spirometry in children capable of
performing the test as well as clinically, by frequency and severity of symptoms and response to
therapy. In children not capable of performing spirometry, clinical characteristics were assessed.
We also obtained 35 age and gender-matched control patient sera as residual samples
from patients undergoing wellness check for school records or general checkup at the University
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of Massachusetts Health Services complex over a similar period of time as the patient samples.
We obtained IRB approval and patient consent to collect and use these residual samples for
research from the Baystate Medical Center and University of Massachusetts Amherst IRB. In
addition, a subset of 20 (of the 197) respiratory disease patients presented with physical airway
anomalies including most commonly, tracheal bronchus, obstruction by a foreign object,
laryngomalacia, tracheomalacia, and bronchomalacia with abnormal cough. These were
considered non-inflammatory controls when compared with asthmatics and patients with
pneumonia and bronchitis.

Chlamydia detection in patient samples
Genomic DNA was isolated from BAL samples and PCR detection of chlamydial DNA was
performed in the same manner as previously described for all samples in this cohort (19). All
BAL samples were also analyzed by tissue culture techniques to determine Chlamydia viability as
previously reported (12, 19). DNA was also isolated from control serum samples in a similar
manner as the BAL and evaluated using the same primers.

Total IgE Evaluation
Total IgE was evaluated using the Elecsys IgE kit (Roche Diagnostics, Indianapolis, IN), with the
electrochemiluminescence immunoassay according to the manufacturer’s instructions. Plates
were read on the Roche Elecsys 1020 analyzer which automatically calculated the IgE
concentration of each sample based on a standard curve. Elevated IgE levels were determined
based on the manufacturer’s recommended threshold by age range.

Isolating Serum and BAL IgE Antibodies
Because the normal concentration for IgE in serum is approximately 0.0005 mg/ml, and is even
less in BAL fluid, we utilized affinity beads in a similar manner as Kadooka et al (20) to isolate
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the IgE antibodies in order to ensure effective reaction of these antibodies with chlamydial
antigens on our blots. We used recombinant Protein G sepharose gel (Sigma-Aldrich, St. Louis,
MO) to adsorb IgG antibodies from the serum samples. Since recombinant protein G does not
bind IgE antibodies (21, 22), individual patient serum samples were added to the beads and
allowed to bind with slow stirring overnight. The supernatant that was now ‘enriched’ for IgE
antibodies was then removed and analyzed for the presence of Chlamydia-specific IgE antibodies.
To test for IgE in BAL samples, recombinant protein A beads (Sigma-Aldrich, St. Louis,
MO) were utilized in the same manner as the protein G beads above. In this case the protein A
beads were used to adsorb any antibodies detectable in the BAL fluid. IgE antibodies present in
the BAL fluid were bound by the protein A beads and the bound antibodies were eluted using a
pH 2.5 glycine solution followed by centrifugation to obtain the supernatant containing IgE and
other antibodies if present. The eluted antibodies were pH balanced using Tris-HCL and then
used as the primary antibody in the Western blot procedure. Because of the limited volume of
some BAL fluid samples available and the low concentration of IgE in each sample, BAL
samples were initially assessed in batches of 4 to 7 samples each.

Western Blot Procedure
As previously reported, Western blot is a highly sensitive and efficient technique in detecting
specific IgE (23-25). C. pneumoniae (TW183) and C. trachomatis (serovar E) elementary bodies
were purified by 20%-50% (vol/vol) Renografin gradient centrifugation as previously described
(26) and normalized for protein content using the Bradford protein assay. Proteins were separated
by electrophoresis on NuPage 4-12% Bis Tris gels (Invitrogen, Carlsbad, CA). Following
electrophoresis the separated proteins were transferred to PVDF membranes, blocked and each
well was cut into individual strips. Each strip was incubated with patient sample that had been
processed with protein A or G beads overnight. After incubation, the strips were washed and a
1:500 dilution of AP-conjugated anti-human IgE, epsilon chain specific antibody (KPL,
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Gaithersburg, Maryland) was added to each strip for 2 hours. Strips were again washed and
developed with a BCIP/NBT alkaline phosphatase substrate and reactions were stopped after
several washes with ultrapure distilled water. Blot strips were analyzed for the presence and
identity of Chlamydia-specific IgE bands. All samples were assayed for the presence of specific
IgE using identical conditions including sample dilution.

Cell Counts
BAL cell counts and differentials were performed according to standard techniques in the
hospital’s Hematology Clinical Laboratory at Baystate Medical Center (Springfield, MA) as
previously reported (19, 27). Briefly, cell enumeration was performed manually using a cell
counting chamber under phase microscopy with results expressed as “number of cell/mm3. BAL
differential counts were performed using Wright stained cytospin preparations of BAL and
examination was performed under oil-immersion microscopy (50X or 100X). Results were
expressed on the basis of a 100 cell count survey. Inflammatory asthma sub-phenotypes were
determined based on BAL neutrophil and eosinophil cells counts, as previously reported (28)

Statistical Analysis
All statistical analyses among the different groups of the patient population were performed using
Microsoft Excel®. Statistical correlations were determined with Fisher's exact test and Chi-square
with Yates correction (SPSS 15.0 software). A p-value of 0.05 was considered significant and all
tests were two-tailed.
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Results
Characteristics of Study Patients
We obtained both BAL fluid and serum from 197 pediatric respiratory disease patients,
average age 7.9 years old, who presented to a pediatric pulmonary practice in Springfield, MA
with chronic respiratory disease and were generally unresponsive to corticosteroid treatment. The
patient demographic (Table 8), shows that 143/197 (73%) were diagnosed with asthma and that
these asthmatics were predominantly between the ages of 2 to 10 years old. We utilized a healthy
control group of 35 patients, average age 5.8 years, 21 males/14 females who saw their doctors
for wellness checks. Total serum IgE generally increased with age up to 15.0 years old (40 IU/ml
to 250 IU/ml; see Figure 7). The levels decreased significantly in the 15.1 to 20.0 year old age
group.

Prevalence of Chlamydia in patient cohort
Polymerase chain reaction (PCR) was utilized to determine if C. trachomatis and/or C.
pneumoniae organisms were present in patient BAL samples. A total of 134/197 (68%) patient
samples were positive for chlamydial DNA. Species-specific PCR revealed that 65 samples were
positive for C. pneumoniae DNA only, 34 were positive for C. trachomatis DNA only and 35
patients harbored both C. trachomatis and C. pneumoniae DNA. In order to determine if the
organisms detected by PCR were viable, all BAL samples were subjected to a modified tissue
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Description

Asthma (*percent
within asthma)

Non-asthma
(*percent within
non-asthma)

Total

Diagnosis
Average age
Age range
0-2.0
2.1-5.0
5.1-10.0
10.1-15.0
15.1-20.0

143 (72.6%)
8.3

54 (27.4%)
7.1

197
7.9

14 (9.8%)
38 (26.6%)
41 (28.7%)
29 (20.3%)
21 (14.6%)

16 (29.6%)
13 (24.1%)
8 (14.8%)
9 (16.7%)
8 (14.8%)

30
51
49
38
29

Gender
Female
Male

65 (45.5%)
78 (54.5%)

25 (46.3%)
29 (53.7%)

90
107

Ethnicity
White
Black
Hispanic
Asian

107 (74.8%)
7 (4.9%)
29 (20.3%)
0 (0.0%)

43 (79.6%)
4 (7.4%)
6 (11.1%)
1 (1.9%)

150
11
35
1

BMTH
Yes
No
Not Done

118 (82.5%)
10 (7.0%)
15 (10.5%)

17 (31.5%)
18 (33.3%)
19 (35.2%)

135
28
34

Table 8: Patient demographics of the pediatric patient cohort
Most of the patients in this cohort were asthmatics (72.6%) with an average age of 8.3 years old
(7.9 years old for entire cohort). The majority of asthma patients were between ages 2 to 10 years
old and basement membrane thickening (BMTH) was significantly correlated with asthma
diagnosis.
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Figure 7: Total Serum IgE levels generally increased with age
Assessment of total serum IgE levels showed a general increase with age up to age 15.0 years old
(40 IU/ml to 250 IU/ml). The levels then decreased to 100IU/ml. Dark lines represent the average
IgE level for each age range
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culture technique as previously described. The data showed that 74/197 (38%) patients assayed
were culture positive for Chlamydia. Importantly, 62/74 (84%, (Fisher's exact test p<0.0001)
culture positive patients were diagnosed with chronic, severe asthma according to GINA
guidelines (29). Analyses of the control patient sera revealed that 7/35 (20%) were positive for
the presence of chlamydial DNA.

Total IgE antibody serum levels
Data analysis revealed that 65/197 (33%) patients had elevated serum IgE levels, while
132/197 (67%) had normal IgE levels (Fisher's exact T-test p < 0.0001). Patients who were
positive for Chlamydia by DNA or culture had significantly higher levels of total serum IgE
compared to IgE negative patients (p=0.0071 and p= 0.0001 respectively; Figure 7). Patients who
tested positive for C. pneumoniae specific IgE antibodies also had an average IgE level that was
higher than the specific IgE negative cohort. Total serum IgE generally increased with age up to
15.0 years old (40 IU/ml to 250 IU/ml; see Figure 8). The levels decreased significantly in the
15.1 to 20.0 year old age group.

Chlamydia-specific IgE Antibody is Present in the BAL and Serum of Infected Patients
In light of the increased prevalence of chlamydial organisms in the BAL fluid of patients
in this cohort, patient serum and BAL samples were analyzed to determine the response of the
host to the organism in each case and to determine if there is pathology associated with its
presence. We therefore developed a Western blot assay to determine the presence, prevalence and
identity of Chlamydia-specific IgE in both the serum and BAL fluid from each patient. Since
BAL samples were assessed in batches of 4 to 7 samples each (because of limited sample
volume), we cannot ascertain the exact percentage of patients with Chlamydia-specific IgE in
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Figure 8: Presence of Chlamydia organisms is associated with higher levels of serum IgE
While the average total serum IgE levels in this patient cohort was not significantly elevated (138
IU/ml), IgE levels were significantly more elevated in patients who were either Chlamydia DNA
positive or who had viable organisms as determined by culture. Patients with C. pneumoniaespecific IgE also had an average total IgE level that was higher than their C. pneumoniae-negative
counterparts. Horizontal dark bars represent the average IgE level and each shape in the
respective columns represents a single patient.
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their BAL fluid. However, qualitatively, BAL fluid samples from this patient cohort contained
Chlamydia-specific IgE antibodies (Figure 9). To our knowledge, this is the first report of
pathogen-specific IgE in human BAL fluid.
Chlamydia-specific IgE was also detected in the sera of 107/197 (54%) patients suffering
from chronic respiratory disease but none of the healthy control patient sera (0/35, p < 0.0001). In
addition, a subset of 20 patient samples from our respiratory disease cohort who were diagnosed
with structural anomalies rather than inflammatory airway disease, were also assessed for the
prevalence of Chlamydia-specific IgE. The data shows that 1/20 (5%) had Chlamydia-specific
IgE in their sera compared to the inflammatory patient cohort (Table 9). Assessment to determine
the prevalence of Chlamydia-specific IgE antibodies in the BAL culture-positive patient cohort
showed that 68/74 (91.9%, P=0.0001) tested positive for Chlamydia-specific IgE.
Both C. trachomatis and C. pneumoniae-specific IgE antibodies were found in the BAL
fluid (Figure 10). Importantly, although Chlamydia has 800 – 1000 coding genes, only 6
chlamydial antigens appear to induce pathogen-specific IgE responses in this patient cohort and
the frequency of these bands differ significantly between C. trachomatis and C. pneumoniae
(Figure 10b and 10c). In fact, most of the patient samples contained IgE antibodies to a single
protein band on the blots (see Figure 9).
Overall, 61% of the Chlamydia-specific IgE antibodies in BAL fluid recognized the
chlamydial major outer membrane protein (MOMP). This was generally true however, for C.
pneumoniae IgE antibodies, where 81% of the positive patients had IgE that recognized MOMP,
compared to only 17% for C. trachomatis MOMP. Thirty three percent of BAL fluid positive
patient samples displayed IgE antibodies against an un-annotated 250kDa C. trachomatis protein.
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Figure 9: Western blot of Chlamydia-specific IgE
The blots depict representative patient BAL and serum samples that were positive for the
presence of Chlamydia-specific IgE. Band specificities were determined by a Chlamydia-positive
control and the Chlamydia protein data-base was used to confirm the corresponding protein. Note
that of all the chlamydial proteins seen on the control strip stained with a polyclonal antibody
solution, only a finite number are recognized by specific IgE antibodies.
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Table 9: The Prevalence of Chlamydia-specific IgE in Patient Sera
Fifty five percent of patients with inflammatory respiratory disease had Chlamydia-specific IgE
antibodies in their sera compared to 5% of the 20 patients with structural anomalies and 0% of
healthy controls (p = 0.0030 and 0.0001 respectively. 70% of the patients diagnosed with
respiratory disease also tested positive for chlamydial DNA, whereas only 20% of healthy
controls tested positive for chlamydial DNA (p=0.0208).
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Figure 10: Chlamydia protein molecular weight frequency trends in BAL fluid
Chart A shows the overall molecular weight of proteins recognized by Chlamydia-specific IgE
antibodies from patient BAL samples. These are for C. trachomatis and C. pneumoniae specific
antibodies combined. The major outer membrane protein (MOMP) is recognized 61% of the time
by these positive patient sera. However, chart B clearly shows that the MOMP from C.
pneumoniae organisms were more likely to induce IgE antibodies than C. trachomatis MOMP
(Chart C). The hypothetical 250KDa protein was the most frequently recognized C. trachomatis
protein in BAL.
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Assessment of individual serum samples for the presence of Chlamydia-specific IgE
antibodies revealed bands on Western blot ranging in molecular weight from 6kDa to 250kDa
(Figure 11A). As was true for the IgE antibodies in the BAL fluid, the identity of serum IgE
antibodies produced in response to C. trachomatis were significantly different from C.
pneumoniae – specific antibodies (Figure 11B and C). Antigen frequency analysis revealed that
42% of IgE positive serum samples contained IgE antibodies that recognized C. pneumoniae
chlamydial lipopolysaccharide (cLPS). C. trachomatis - induced cLPS IgE antibodies were not
detected in any serum sample. C. pneumoniae did not induce MOMP-specific IgE in serum,
while 8% of IgE positive-patients had antibodies that recognized C. trachomatis MOMP (Figure
11C). There were also significant differences in the production of Chlamydia-specific IgE in the
serum versus BAL fluid. Chlamydial heat shock protein 60 (Hsp 60 or GroES) and the
polymorphic outer membrane protein (POMP) did not induce IgE antibodies in the BAL fluid,
however, they each accounted for the Chlamydia-specific IgE found in 20% of positive patient
sera assayed. The frequency of MOMP-induced IgE in the BAL fluid was 61%, while the
frequency in serum was only 5%, demonstrating possible site-specific differential cytokine and
lymphocyte responses or antibody release (see figures 10A and 10A).

Inflammatory asthma phenotype and serum IgE concentrations
Eosinophilic inflammation, characterized by high levels of eosinophils, atopy and
elevated serum IgE concentration, has long been considered one of the most distinctive
pathological hallmarks of asthma (30). However, it has recently been recognized that airway
eosinophilia is not a universal finding and a significant subset of patients with refractory asthma
display a non-eosinophilic phenotype. BAL cell counts revealed that 115/143 (80%) asthma
patients in this cohort presented with a non-eosinophilic inflammatory asthma phenotype.
Overall, the majority of patients in this cohort 166/197 (84%) had normal BAL eosinophil counts.
Asthmatic patients had a significantly higher total IgE level compared to non-asthmatic patients
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and patients with an eosinophilic asthma phenotype had significantly higher total serum IgE
levels than other inflammatory asthma groups (p = 0.0001; see Figure 12).
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Figure 11: Chlamydia protein molecular weight frequency trends in serum
Unlike the BAL fluid proteins in figure 2, serum IgE antibodies against MOMP only appeared in
5% of the patients tested, while the other 5 antigens appeared at similar frequency to that of the
BAL (Chart A). Closer analysis shows that while serum IgE antibodies recognized C.
pneumoniae LPS in 42% of positive samples (Chart B), no C. trachomatis LPS was recognized
by these samples (Chart C). Although MOMP is the major antigen on the chlamydial EB surface,
C. pneumoniae MOMP did not induce serum IgE production in this study.
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Figure 12: Asthma phenotypes and total serum IgE levels
Asthmatic patients had significantly higher total IgE levels compared to non-asthmatic patients.
Inflammatory asthma phenotypes determined by BAL cell counts revealed that eosinophilic
asthmatics had higher IgE levels compared to non-eosinophilic phenotypes (neutrophilic,
paucigranulocytic and mixed granulocytic patients).
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DISCUSSION
The nature of the clinical association that exists between Chlamydia airway infection and
subsequent development of asthma in young children remains controversial. In an effort to find
discriminative serological or biological markers to differentiate between patients with infectionmediated airway responsiveness and those with other aeroallergen-specific disease, we utilized
Western blot techniques to determine and compare the Chlamydia-specific IgE response in the
sera of 197 pediatric patients with chronic, severe respiratory disease.
The development of pathogen-specific IgE antibodies is not unique to Chlamydia
infection. Numerous reports have demonstrated production of specific IgE antibodies in response
to infection by pathogens, including a variety of viruses (31-33) and Mycoplasma (34). Emre et
al, previously reported the presence of C. pneumoniae-specific IgE in a cohort of children with
chronic respiratory disease, and suggested that production of specific IgE may be an underlying
mechanism leading to reactive airway disease in some patients with C. pneumoniae infection
(35). With our larger cohort, our data is in line with this previous report and is strongly predictive
of severe reactive airway disease and poor asthma outcome. To this end, while the role of
pathogen-specific IgE antibodies has still not been fully determined, when studied, in most cases,
the responses were associated with a poorer prognosis (33).
Approximately 68% of the patients analyzed in the current study harbored chlamydial
DNA and 54% produced detectable levels of specific IgE antibodies in response to chlamydial
infection. Age matched, healthy controls had no detectable Chlamydia-specific IgE in their
serum. There was also a significant association between the presence of Chlamydia-specific IgE
antibodies in the serum and cultivable Chlamydia from BAL fluid, suggesting that the presence of
viable, actively replicating organisms are more likely to induce pathogen-specific IgE production
and could therefore lead to greater allergic type pathology. A limitation of the current study
however, is that we were not able to assess individual BAL samples for the presence of
Chlamydia-specific IgE because of limited sample volume and therefore have only qualitative
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data on BAL IgE from pools of 4 – 6 samples. However, we assessed individual serum samples
that showed similar banding patterns as the pooled BAL samples. A second limitation is that our
control cohort consisted of only 35 patients and we did not obtain BAL samples from these
patients since this is a highly invasive procedure. These patients were not assessed clinically for
any respiratory disease since they appeared healthy upon physical examination as part of a
wellness checkup by a primary care physician. However, compared to the respiratory disease
population, these healthy controls did not have Chlamydia-specific IgE antibodies in their sera,
suggesting that this phenomenon is specific to a chronic, severe, respiratory disease.
Chlamydial antigens recognized by specific IgE antibodies were significantly different in
the BAL and serum for C. trachomatis versus C. pneumoniae. It is not clear at the present time
why these dramatic differences in antigen recognition exist. However, only 6 chlamydial antigens
were recognized by either BAL or serum specific IgE in this patient cohort. The only obvious
unique quality about these antigens is that they are surface exposed or secreted by the organism.
We have assessed these proteins by utilizing reducing and non-reducing SDS-PAGE conditions
with the same results. We confirmed the identity of the MOMP protein and the cLPS antigen
using recombinant proteins but used the Chlamydia protein data base to match the most likely
molecular weight for the other antigens. Further assessment of the patient cohort for the presence
and level of total IgE confirmed that only 31% of patients who had Chlamydia-specific IgE had
an overall elevated IgE level. This strongly suggests that patients who are assessed as non-atopic
may nonetheless produce Chlamydia-specific IgE, which we hypothesize, could lead to airway
pathology.
The primary biological function of IgE is to provide immunity against multicellular
parasitic pathogens (36). However, in developed countries with good sanitation where parasitic
diseases are rare, IgE responses are most often directed against innocuous allergens resulting in
type I allergic disease. Mouse-model studies have consistently demonstrated that inhalation of
innocuous aerosolized protein antigens typically does not induce antigen-specific Th2 responses
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leading to IgE production (37). However, it has been demonstrated that ongoing Th2 responses
produced either by antigen challenge or infection during antigen inhalation can prevent the
establishment of aerosol-induced IgE tolerance and lead instead to Th2 priming (38). It is
possible as suggested by Hollams et al (39), that upon bacterial infection Th2 cytokines may just
be suppressing other pro-inflammatory cytokines, such as tumor necrosis factor-α and IL-1, as
well as mediators such as prostaglandin, hence, counter-regulating the increased Th1 immune
responses. However, since C. pneumoniae surface antigens have to be processed and presented by
antigen presenting cells (APC) to activate T-cells and, thus, may not directly induce a Th2
response, this theory might not hold true in this case.
C. pneumoniae has long been implicated in the inflammatory response experienced by
chronic asthmatics; however, a specific mechanism of its involvement has remained elusive.
While the role and regulation of IgE antibodies towards microbial antigens is far from being
elucidated, results from the current study strongly suggest that this obligate intracellular pathogen
can induce pathogen-specific IgE production and could therefore lead to mast cell degranulation
and release of vasoactive agents. The presence of Chlamydia-specific IgE in the serum would
suggest that the organisms play a direct role in asthma pathogenesis by continuous induction of
IgE, since unlike most aeroallergens that a patient can avoid, the chlamydial organisms reside in
the lower airways and are continuously secreting bacterial antigens. In addition, even if the
organism is cleared by antibiotic use or natural immune responses, Chlamydia – specific IgE
antibodies might still play an important role in the development of exaggerated airway
responsiveness during subsequent subclinical or even asymptomatic infection.
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CHAPTER 4
COLONIZATION OF THE PAEDIATRIC LOWER RESPIRATORY TRACT WITH
GENITAL MYCOPLASMA SPECIES
Abstract
Background and Objectives: Recently, much attention has been given to the possible role
played by pathogens that colonize neonatal or pediatric airway and their potential involvement in
chronic respiratory disease. While Mycoplasma pneumoniae has been implicated in various acute
and chronic respiratory diseases, the genital Mycoplasma species have not been studied. The goal
of the current study was to evaluate the prevalence of urogenital Mycoplasma organisms in the
bronchial lavage (BAL) fluid of pediatric patients suffering from a variety of chronic respiratory
diseases to determine if there was any clear disease association.
Methods: We examined 319 pediatric BAL samples for the presence of M. genitalium, M.
hominis, U. urealyticum, U. parvum and M. pneumoniae DNA via PCR using species-specific
primers.
Results: Mycoplasma DNA was found in 104/319 (32.6%) patient samples; 32/104 (30.8%) were
positive for M. pneumoniae; 28/104 (26.9%) for U. parvum; 99/104 (8.6%) for U. urealyticum;
15/104 (14.4%) for M. hominis and 29/104 (27.9%) for M. genitalium. There were ten 16S DNApositive samples that remained unidentified and 16 patient samples contained two or more
species.
Conclusions: Our data indicate that in addition to M. pneumoniae, urogenital Mycoplasma
species may colonize the airway of patients with chronic respiratory diseases. There was
however, no association between chronic asthma and Mycoplasma colonization in this study.

Introduction
Chronic respiratory diseases, airway inflammation, chronic pneumonia and chronic
obstructive pulmonary disease, are known to be associated with chronic infections. Mycoplasma
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pneumoniae is a common cause of upper and lower respiratory tract infections in persons of all
ages and according to many reports, may be responsible for up to 40% of community-acquired
pneumonias (1). Mycoplasma pneumoniae can cause pharyngitis, otitis, and tracheobronchitis,
but may also remain asymptomatic (2). Recent research indicates that like infections due to
Chlamydia pneumoniae or to viruses, acute M. pneumoniae infection may not only promote the
exacerbation of asthmatic symptoms but also may be accompanied by wheezing in non-asthmatic
children (3-6). However, after years of research and much debate, the significance of these
organisms in chronic respiratory disease is still under investigation and remains unclear. Despite
the experimental evidence for an association between lower airway infection and chronic asthma,
testing patients for such infections in the clinical setting is problematic. In recent studies, subjects
seronegative for M. pneumoniae tested PCR-positive for the bacterial DNA, clearly suggesting
that seropositivity is not a reliable marker for Mycoplasma infection of the airways and hints at
the fact that other species might be the source of the DNA (7). The urogenital mycoplasmas
represent a complex and unique group of microorganisms that have been associated with a wide
array of infectious diseases in adults and infants (8).

Mycoplasma hominis, Mycoplasma

genitalium and Ureaplasma species, known collectively as the genital mycoplasmal organisms,
are generally considered opportunists that cause invasive infections in susceptible populations.
These genital strains of Mycoplasma have been detected in more than 12% of females who
presented at gynecological services, and have been associated with acute and nonspecific, nongonococcal urethritis (9), with M. hominis and M. genitalium assuming increasing importance as
neonatal pathogens (10). Ureaplasmas have been isolated from the endotracheal secretions in up
to 40% of newborn infants within 30 min to 24 h after birth (11). In 1999 the Ureaplasmas were
divided into two biovars on the basis of phylogenetic analysis. Strains classified as biovar 1 were
designated as a separate species, Ureaplasma parvum, whereas strains with biovar 2 traits
retained the U. urealyticum designation (12, 13). Recently, it has been reported that intrauterine
infection of U. parvum can cause congenital pneumonia and sepsis even in term newborns (14).
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New studies suggest that U. urealyticum and U. parvum may be an important cause of lung injury
in newborns and neonates through a number of mechanisms including the inhibition of
pulmonary surfactant as well as the production of interleukins and soluble intercellular adhesion
molecules (15). In the current study, we examined BAL from children with a variety of chronic
respiratory conditions to determine the prevalence of both genital and respiratory associated
Mycoplasmas as well as to establish if there is an association between DNA evidence of the
bacteria and specific diseases in this pediatric cohort.

Materials and Methods
Patients and Specimens
Residual BAL collected for clinical reasons from patients with an array of chronic respiratory
diseases undergoing diagnostic bronchoscopy procedures with lavage under an IRB-approved
protocol at Baystate Medical Center (BMC), a community/academic hospital setting in
Springfield MA, over the period from July 2003 to July 2009 were used for this study. Children
were referred for bronchoscopy only after thorough evaluation did not yield a definitive diagnosis
or after medical management did not produce an adequate improvement in their clinical
condition. Specifically, the children in this study were considered for bronchoscopy because 1)
their symptoms were not improving with treatment over time, 2) non-invasive methods did not
generate a definitive diagnosis, 3) aggressive medical management had not been successful and 4)
the child was truly compromised, missing multiple school days, excluded from physical activity
and presenting with recurring symptoms. Many patients presented with severe persistent asthma
which was poorly responsive to maximal medical therapy or infection was suspected. The criteria
for bronchoscopy followed in this study has been previously described (16). This study was
approved by the BMC Institutional Review Board and complied with the ethical guidelines of
BMC and the University of Massachusetts. Informed consent was obtained from all patients or
their guardians prior to specimen collection.
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PCR Analysis
Upon arrival to the research lab, genomic DNA was isolated from each BAL sample using the
QIAMP DNA Blood mini kit (Qiagen). All original samples and isolated DNA were stored in a 80°C freezer until time of testing. Polymerase chain reaction (PCR) was used to detect
Mycoplasma DNA. All samples were processed using best practices to reduce DNA
contamination including wearing clean lab coats and fresh gloves, maintaining separate areas and
dedicated equipment and supplies for sample preparation, setup, amplification and analysis of
PCR products. Lab benches and equipment are periodically cleaned with a 10% bleach solution
and positive-displacement pipets along with pipet tips containing hydrophobic filters are a
standard part of DNA work in the lab. Mycoplasma 16S and M. pneumoniae specific PCR was
performed using commercial kits (Maxim Biotech, Inc. Mycoplasma 16S rRNA kit-SP-10521 and
PCR Primer Amplification Kit, Mycoplasma pneumoniae, Attachment Protein P1; SP-10523)
according to the manufacturers guidelines. M. hominis, M. genitalium, and U. urealyticum were
specifically detected using previously published primers and protocols: Mh fwd and rev (334 bp),
Mg fwd and rev (425 bp), and UMS 170 and UMA 263r (476 bp) respectively (13, 17, 18). U.
parvum positive samples were further tested using previously published U. parvum serovars 1, 3,
6, and 14 specific, previously published primers (13). All serovars of U. parvum were initially
detected using UMS 57 and UMA 222 primers (327bp). Subsequent amplicon sizes of 398 bp,
442 bp, or 369 bp were considered to be positive for serovar 1, serovars 3/14, and serovar 6 of U.
parvum, respectively (13). The PCR products were separated by electrophoresis on a 2% agarose
gel and visualized by staining with ethidium bromide. Photographs were taken with the Syngene
GeneFlash gel documentation system [Syngene USA, Frederick, MD].

BAL Cell Counts
BAL cell counts were performed as previously reported (19). Briefly, cell enumeration was
performed manually using a cell counting chamber with a phase contrast microscope. The results
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are expressed as “number of cells per cubic millimeter.” Differential counts were performed with
Wright stained cytospin preparations of BAL. Results were expressed on the basis of a 100 cell
count survey. Inflammatory asthma sub-phenotypes were determined based on BAL neutrophil
and eosinophil cells counts, as previously reported (20, 21).

Endobronchial Biopsy Eosinophil counts
Where performed, the endobronchial specimens were preserved in formalin, processed, and
embedded in paraffin. Routine histological sections were cut at 5μm in thickness and stained with
hematoxylin-eosin. The presence of eosinophils was determined by their characteristic bilobed
nucleus and eosin-staining granules within the cytoplasm.

Evaluation of Total IgE
Total IgE was performed using the Elecsys IgE kit (Roche Diagnostics, Indianapolis, IN). This kit
utilized the electrochemiluminescence immunoassay and tests were performed according to the
manufacturer’s instructions. Plates were read on the Roche Elecsys 1020 analyzer which
automatically calculated the IgE concentration of each sample based on a standard curve.
Elevated IgE levels were determined based on the manufacturer’s recommended threshold by age
range (neonates, 3·6 ng/ml; infants in first year of life, 36 ng/ml; children aged 1–5 years, 144
ng/ml; children aged 6–9 years, 216 ng/ml; children aged 10–15 years, 480 ng/ml; adults, 240
ng/ml).

Statistical Analysis
Data were analyzed using Microsoft Excel® spread sheets as well as the SPSS 15.0 Graduate
Pack [SPSS, Inc., Chicago, IL] statistics programs. Cross-tabs with the Fisher exact T test and
Chi-Squared test were used to determine significance. T tests were two-sided, and the level of
significance was p ≤ 0.05.
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Results
Characteristics of study participants
The study population consisted of 319 pediatric patients and was made up of 145 females
and 174 males from White (228), Black (24), Hispanic (66) and Asian (1) ethnicity. The average
age of this cohort was 7.9 years old and 225 were diagnosed with chronic asthma (Table 10). The
asthmatics fulfilled criteria for asthma diagnosis and classification of asthma severity in
accordance with GINA guidelines and Recommendations of the National Asthma Education and
Prevention Program guidelines (22, 23).

Through biopsy evaluation, basement membrane

thickening (BMTH) was observed in 77.8% of asthma patients compared to non-asthmatics (P<
0.0001). Respiratory disorders in the non-asthmatic group included aspiration pneumonia, cystic
fibrosis, bronchitis, immune deficiency, gastroesophageal reflux disease, structural and airway
anomalies, and recurrent pneumonia of unknown etiology. There was no correlation between
Mycoplasma DNA positivity and gender (51 females and 53 males). A total of 17 patients were
being prescribed antibiotics at the time of sample collection (11 of these were taking macrolide
antibiotics).
BAL cellularity was assessed to determine if there was an association with the presence
of Mycoplasma DNA in the lungs of patients and the presence of cellular pathology. As shown in
table 1, there was no statistically significant association between the presence of Mycoplasma
organisms and changes in the numbers of immune cells in the BAL fluid analyzed.
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Table 10: Characteristics of Patient Cohort.
Cohort demographics of 319 pediatric patients with an average age of 7·9 years old. There was no
significant link between cell types found in the BAL fluid and the presence of Mycoplasma DNA.
Inflammatory asthma phenotype was based in eosinophil and neutrophil counts in the BAL fluid
and biopsy eosinophils were assessed in fixed H&E stained sections. *Other was mostly epithelial
cells in this study.
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Analysis of serum IgE in this cohort revealed that these antibodies were elevated in a
total of 109 (34% of all patients tested). Elevated levels of IgE were found more often in
Mycoplasma negative patients than patients with bacterial DNA, 85/109 vs. 24/109 respectively,
Fisher exact T test, P < 0.0001, see Table10. While the majority of patients displayed a noneosinophilic asthma phenotype, there was no significant correlation between the finding of
Mycoplasma organisms and inflammatory asthma phenotypes.

Frequency of Mycoplasma DNA in BAL fluid
We previously reported on the prevalence of C. trachomatis and C. pneumoniae in a
subset of this cohort and demonstrated that genital strains of Chlamydia were just as prevalent as
the respiratory strains (19). The current study utilized a PCR assay that amplified the 16S DNA
of all Mycoplasma species in the BAL of our patient cohort in order to determine the frequency of
these organisms in the lungs. The data revealed that 104/319 (32.6%) patient samples contained
Mycoplasma DNA. Assessment of disease association based on asthma diagnosis confirmed that
Mycoplasma 16S DNA was more frequently associated with an asthma diagnosis (69/104 vs.
35/104; p=0.007 Fisher's exact test, two-tailed). However, there was no statistical association
between any of the Mycoplasma species tested and an asthma diagnosis (see Table 11).

Genital Mycoplasma by patient age range and asthma diagnosis
While M. pneumoniae is routinely assayed for in respiratory disease and we have
epidemiological evidence of its frequency, very little is known about the frequency of genital
Mycoplasmas in respiratory disease. Species-specific primers were therefore used to assess the
frequency of five relevant species based on previous reports. Of the 104 patient samples positive
for Mycoplasma DNA, 32 (30%) were M. pneumoniae positive, 29 (28%) were positive for M.
genitalium, 15 (14%) were positive for M. hominis, 28 (27%) were positive for U. parvum, and 9
(9%) were positive for U. urealyticum (Table 11).
76

U. parvum positive samples were further

tested using serovar-specific primers and revealed that 4/28 (14.3%) were U. parvum serovar 1;
5/28 (17.9%) were U. parvum serovar 6, and 22/28 (78.6%) were U. parvum serovars 3 and/or 14.
Three samples were positive for more than one serovars. Ten of the Mycoplasma 16S DNA
positive samples were not identified by any of our species-specific primers and 19 samples
contained combinations of two or three different species. Figure 13 shows representative agarose
gels with PCR products for each of the species tested.
We previously reported the frequency of C. trachomatis in the BAL of pediatric patients
with chronic respiratory disease and presented evidence confirming that the organisms were
acquired as the neonates passed through the birth canal (19). Here, the patient cohort was
assessed to determine if there were trends in the prevalence of Mycoplasma DNA according to
patient age range which would indicate if younger children were more likely to harbor the
organisms. M. genitalium was just as prevalent in the 0-5 year old age group as M. pneumoniae
and generally decreased with an increase in age (Figure 14). M. hominis and U. urealyticum were
also most prevalent in the 0-5 age group but declined dramatically in prevalence in older age
groups.

Unlike M. hominis and U. urealyticum, U. parvum generally remained constant

throughout the pediatric age range and peaked in the 15-20 year old age group. Importantly, M.
pneumoniae was responsible for only 30% of all Mycoplasmas found in the lungs of this pediatric
population.
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Mycoplasma Species

Asthma (N=225)

Non-Asthma (N=94)

P Value

Mycoplasma 16s (N=104)

69 (30.6%)

35 (37.2%)

P=0.4621

M. pneumoniae (N=32)

18 (8%)

14 (14.9%)

P=0.1090

M. genitalium (N=29)

18 (8%)

11 (11.7%)

P=0.3982

M. hominis (N=15)

9 (4%)

6 (6.4%)

P=0.3951

U. parvum (N=28)

19 (8.4%)

9 (9.6%)

P=0.8297

U. urealyticum (N=9)

6 (2.6%)

3 (3.2%)

P=0.7271

Mycoplasma Negative (N=215)

156 (69.3%)

59 (62.8%)

P=0.6270

Table 11: Prevalence of Mycoplasma Species in BAL Fluid by Disease Diagnosis
Of the 104 patient samples harboring Mycoplasma DNA in their lower airways, 69 (66.3%) were
diagnosed asthmatics (p= 0.007). There was no significant difference between the number of
asthmatic and non-asthmatic patients with M. pneumoniae, U. urealyticum, M. hominis, M.
genitalium, or U. parvum in their lungs.
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Figure 13: Representative agarose gel showing PCR products of Mycoplasma DNA
Each lane represents an individual patient BAL sample with sample code number. Pos and neg.
represent the positive and negative controls respectively and the bp # represents the product size.
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Figure 14: Mycoplasma prevalence according to age
Mycoplasma DNA was more prevalent in the 0-5 year old age range with M. genitalium
accounting for the same number as M. pneumoniae in this age group. All species except U.
parvum, which remained relatively constant, generally decreased over the age range from 0 to 20
years old.
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Seasonal Variation of Mycoplasma Infections
Previous reports have described a seasonal variation in Mycoplasma infections,
highlighting its prevalence in the midsummer and winter months (24, 25). The peak incidence of
Mycoplasma 16S DNA was in the mid-summer month of July (Figure 15A). However, elevated
numbers of patients harboring Mycoplasma DNA in their lungs were also seen during the late fall
to winter months, with numbers higher in the months of November, December, January and
February. Genital strains of Mycoplasma (U. Urealyticum, U. parvum, M. hominis, and M.
genitalium combined) and M. pneumoniae also peaked in prevalence in July, and to a lesser
extent increased once again during fall and winter months. We determined that the increase in
Mycoplasma incidence in the month of July was not due to increased patient sample collection in
that month. The data was expressed relative to the total number of BAL samples for each month
and demonstrated that the months of November to March had an overall greater number of BAL
procedures performed without similar increases in Mycoplasma-positive outcomes (figure 16).
With respect to the peak prevalence of M. pneumoniae, these patient samples were collected year
round over a 6 year period, thereby negating the probability that this trend is the result of a single
outbreak in a particular year. There was no indication of a Mycoplasma epidemic over this time
period with each year showing similar prevalence rates (Figure 15B).
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A

B

Figure 15: Seasonal variations of Mycoplasma species incidence in pediatric lung disease
BAL samples were collected over the course of 6 years and tested by PCR for the presence of
Mycoplasma DNA in a species-specific manner. The highest prevalence of Mycoplasmas in these
patient samples was in samples collected in the month of July. Mycoplasma prevalence was also
generally higher in the late fall to early winter months. Mycoplasma prevalence was highest in
2007-2008.
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Figure 16: Monthly prevalence of patient BAL samples and Mycoplasma positivity
Analysis of the distribution of total patient samples collected per month was compared to the total
number of Mycoplasma-positive samples to determine if the increased positivity seen in the
month of July was influenced by the total number of samples tested for that month. The data
revealed that Mycoplasma positivity is not a reflection of increased monthly prevalence.
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Discussion
Mycoplasma and Ureaplasma organisms can be isolated with considerable frequency
from the female urogenital tract and are thought to cause a wide range of syndromes including
nongonococcal urethritis, cervicitis, amnionitis, pyelonephritis, post-partum septicemia, neonatal
pneumonia, neonatal conjunctivitis, pelvic inflammatory disease, infertility, low birth weight
infants, and premature rupture of membranes (26).

Mycoplasma hominis and Ureaplasma

urealyticum are the most common isolates from the genital tract and may be present as normal
flora in up to 40% of asymptomatic males and females. The urogenital Mycoplasmas have
previously been associated with respiratory distress in newborns (26) and neonatal meningitis
(27), while the Ureaplasmas have been linked with preterm labor (28), intrauterine lung disease
(29), and neonatal pneumonia (30).
The data presented here from analysis of 319 pediatric respiratory disease patients
demonstrated no association between an asthma diagnosis and the presence of respiratory or
genital Mycoplasma species. While it has been recognized as a common respiratory pathogen, M.
pneumoniae accounted for only 30% of Mycoplasma organisms in the lungs of this pediatric
cohort. It is not clear what role, if any, the urogenital Mycoplasmas and Ureaplasma play in acute
or chronic respiratory disease, and clinical labs do not routinely test for these urogenital strains in
respiratory samples. These data suggest that a negative M. pneumoniae PCR test does not
necessarily mean that Mycoplasma is absent. Increasing evidence suggests that urogenital
Mycoplasmas can be the cause of serious extra-genital infections, mainly in immunocompromised
patients although extragenital infections are uncommon in healthy patients and cases of
pneumonia are exceptional (31). In the current study, M. genitalium was the most frequent
urogenital strain isolated from BAL fluid. Species identification of the Ureaplasma biovars
revealed that U. parvum was more commonly isolated than U. urealyticum as reported by other
studies (32), with U. parvum serovars 3/14 accounting for the majority of cases (78.6% of all U.
parvum isolated).
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There are, however, limitations to our investigation. All samples were obtained from a
convenient population of patients with poorly-controlled, chronic respiratory disease who
underwent diagnostic bronchoscopy. Therefore, our results may not be broadly applicable to the
majority of patients whose respiratory disease is readily controlled and are seen in a regular
primary care setting. In addition, we did not have a healthy control population, leaving open the
possibility that the prevalence of both genital and respiratory Mycoplasmas in our test cohort is
reflective of the carriage in the healthy population.
It has been estimated that more than 2 million cases of M. pneumoniae infections occur
annually, accounting for approximately 20% of community-acquired pneumonias requiring
hospitalization and probably an even greater proportion of those that do not(33). While M.
pneumoniae disease tends to be non-seasonal, there are generally increases in late summer and
early fall months (33). This was indeed the case with our sample set, demonstrating highest
prevalence in July. However, there was also an increase in M. pneumoniae prevalence in early
winter months. It is probably valuable to note that late summer to early fall are generally times
when children head back to school, and communal attendance in class may spur a
Mycoplasma infection. In fact all of the Mycoplasma and Ureaplasma organisms assayed in this
study showed seasonal variations. Although limited by the fact that only one sample was
collected from each patient and we therefore cannot comment on the status of infection in
individual patients over time, data from vaginal versus C-section birth as previously reported
(19), suggest that the genital strains of the organisms were acquired for the most parts at the time
of birth through the birth canal. Moreover, further investigation did not reveal a Mycoplasma
epidemic over the period of the study.
Ongoing research into the importance of atypical pathogens in chronic respiratory
diseases, including asthma will further elucidate whether these infections are important in disease
development or whether their prevalence is increased in subjects due to chronic airway
inflammation or other, yet unidentified, predisposing factors. Prolonged proinflammatory
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responses initiated by Mycoplasma infections could contribute to altered developmental signaling
in the immature lung and may lead to long-term respiratory problems (34). Increasingly, basic
and clinical research suggest that genital strains of Mycoplasma can cause respiratory disease not
just in immunocompromised, but even healthy adults and children and are often not easy to
identify or treat (31). While we did not find a definitive link between the presence of individual
organisms and chronic lung disease in this study cohort, Mycoplasma 16S DNA was found more
often in asthmatic patients. Therefore, the presence of urogenital Mycoplasma species should not
be underestimated, but rather evaluated in patients with chronic respiratory diseases, especially in
those whose symptoms have not improved over time with standard therapy.
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CHAPTER 5
EVIDENCE OF INFECTIOUS ASTHMA PHENOTYPE: CHLAMYDIA-INDUCED
ALLERGY AND PATHOGEN-SPECIFIC IgE IN A NEONATAL MOUSE MODEL
Abstract
Rationale: Asthma is a chronic respiratory disease whose etiology is poorly understood. Recent
studies suggest that early-life respiratory infections with atypical bacteria may play an important
role in the induction/exacerbation of chronic respiratory disease.
Purpose: The current study utilized a neonatal mouse ovalbumin (OVA) sensitization model of
asthma to determine the course of early-life respiratory tract infection by Chlamydia.
Methods: Neonatal (day 1) and adult (6 wks) BALB/c mice were infected intranasally with
Chlamydia (MoPn) and 7 weeks later were sensitized and challenged with ovalbumin. Allergic
airway disease was characterized by examination of serum and bronchoalveolar lavage fluid
(BAL) cellularity, cytokine production and antibody response. The presence of Chlamydia was
determined by PCR and culture. Ova-specific IgE was quantified by ELISA and Chlamydiaspecific IgE was determined via Western blot analysis.
Results: Chlamydial infection in neonatal mice induced increased production of Th2 cytokines
(IL-4, 5, 10, and 13) in both BAL and serum, while infected adult mice produced increased Th1
cytokines (IL-2, IFN-γ). The BAL from infected neonates contained significantly elevated levels
of eosinophils compared to infected adult mice. Although adult mice cleared the infection ~30
days post infection (pi), neonates were still infected 66 days after initial infection. Chlamydiaspecific IgE was detected in both BAL and serum of neonatal mice beginning 28 days post
infection, however, infected adult mice did not produce Chlamydia-specific IgE antibodies over
the course of the study. When allergic airway was induced using Ova albumin, infected neonatal
mice increased their production of IL-4, IL-5 and IL-13 by >2 fold compared to uninfected
controls and infected adult groups.
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Conclusions: Our findings demonstrate that early-life Chlamydia infection induces a Th2dominant cytokine response in the airways of neonatal mice, leading to chronic infection. More
significantly, early life respiratory colonization with Chlamydia elicits pathogen-specific IgE
production, which provides further evidence of an infectious asthma phenotype.

Introduction
According to the most recent available data, the total incremental cost of asthma to
society was $56 billion, with productivity losses due to morbidity accounting for $3.8 billion and
productivity losses due to mortality accounting for $2.1 billion (1). Over the last 2 to 3 decades
there has been a significant increase in asthma prevalence in Western countries and recent data
suggests that while these levels might be peaking, many low and middle income countries are
now beginning to experience increases in prevalence (2). Until recently it was widely believed
that asthma was an atopic disease caused by allergen exposure and many that the global increases
in asthma prevalence are due to increases in exposure to aeroallergens which lead to eosinophilic
infiltration, mast cell degranulation, hyper-responsiveness and airflow obstruction; and was
fundamentally linked to a patient’s genetic inheritance (2, 3).

However, it is becoming

increasingly evident that this allergen-mediated, eosinophilic airways inflammation model is an
overly simplified explanation of this very complex disease and that no single etiology can be
defined to date (4). While it is indisputable that there are many clear cases of allergen exposure
leading to asthma development in adults, overall there is little evidence that allergen exposure is a
major primary cause of asthma in children, and even some evidence that allergen exposure early
in life may have a protective effect (3). Moreover, recent studies support the conclusion that nonallergic or non-eosinophilic airways inflammation may account for over half of all asthma cases
(5). Eosinophilic asthma is now classified as a distinct asthma phenotype that is characterized
pathologically by significant basement membrane thickening and pharmacologically by
corticosteroid responsiveness. In contrast, non-eosinophilic asthma, that includes most patients
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with severe disease, has very little basement membrane thickening of the basement appears to be
relatively corticosteroid resistant (6). These published reports strongly suggest that despite
clinically similar features, not all asthma is the same and patients may therefore benefit from
personalized treatment. Moreover, surveys have consistently shown that many patients with
asthma do not have their disease well controlled. A recent CHOICE survey study concluded that
of all asthma patients on controllers, only 14.3% were well controlled (7). However, before these
patients can be effectively treated, a better understanding of non-allergic asthma etiology is
necessary.
Since allergic asthma seems to be a Th2-disease, immunomodulating factors such as
early childhood infections, LPS-exposure or other factors influencing gene-environment
interaction and individual susceptibility might be relevant for the development of
childhood asthma (8). The hygiene hypothesis suggests that early-life infections are crucial in
shaping and developing dominant immune responses; it also suggests that exposure to Th1inducing pathogens is essential so that neonates can mount protective Th1 responses in later life
(9). However, recent findings are clearly suggesting that while exposure to certain infectious
microbes can protect from atopy, other infections appear to promote allergic diseases. It now
appears that the timing of exposure to infection, the virulence properties of the infectious agent,
and the genetic susceptibility of the host, all play an important role in the future development of
allergic disease (9). It has been shown that neonatal immunity is limited in its ability to generate
strong Th1 responses to infection. Although chlamydial infections induce and are ultimately
cleared by TH1-mediated immune responses, clinical studies link chlamydial lung infection with
the development of asthma in children (10, 11). Indeed, a recent study from our lab showed that
over 68% of children with asthma harbored viable Chlamydia in their lungs and that atopy was
strongly associated with infection (12).

These data suggest that only in some predisposed

individuals does infection induce Th2 responses (12). To this end Hansbro et al have proposed
two hypotheses to explain the association between TH1-inducing infections and asthma (13). The
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first is that neonatal responses to infection are highly polarized towards TH2 immunity and thus
early life chlamydial infection in neonates reinforces rather than suppresses this response, which
leads to atypical TH2 responses to the infection (13). This has the potential to drive the immune
system to develop an allergic phenotype, which can ultimately lead to persistent infection and
increasing the severity of TH2-type inflammatory responses to environmental antigens, and drive
asthma disease. The second hypothesis is that TH1-inducing infections may cause a generalized
inflammation of the airways that leads to the exacerbation of allergen-induced inflammation and
asthma later in life (13).
Previously published data from our lab demonstrates strong evidence linking Chlamydia
pneumoniae infection with the development and exacerbation of asthma in pediatric patients. C.
pneumoniae has, therefore, been associated with both protective (Th1) as well as pro-asthmatic
(Th2) immune responses. As a corollary, and in an attempt to better understand the mechanisms
involved, we utilized a mouse model to investigate whether chlamydial infection in early life
stimulates protective immunity or drives Th2 responses leading to the development and/or
exacerbation of asthma later in life. We utilized a murine ovalbumin (Ova)-induced allergic
airway disease (AAD) model that was previously developed and refined by Horvat, et al (14) to
determine the impact of early life chlamydial infection on the subsequent development of AAD in
adulthood.

Materials & Methods
Mouse Models
For neonatal experiments, pregnant BALB/c mice were purchased from Jackson Labs (Bar
Harbor, ME) and used with the approval of the IACUC, University of Massachusetts Amherst.
Within 1 hour of birth (Day 0) mice were infected intranasally (IN) with C. muridarum, formerly
known as the mouse pneumonitis biovar of C. trachomatis (approximately 200 inclusion-forming
units (IFU) in 5µl sucrose phosphate-glutamate buffer, SPG).
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For adult experiments, 5 week old virgin female BALB/c mice were utilized. The groups
of adult mice were treated in a similar manner as the newborns. Adult mice were anaesthetized by
isoflurane inhalation, held in the upright position and the inoculum, 200 IFU in sucrose phosphate
glutamate buffer (SPG, 50ul final volume), was pipetted onto the nares until the whole inoculum
was inhaled. Control mice for both groups received equivalent volumes of SPG via a similar
route.
Seven weeks post infection/placebo treatment (Day 50) mice were sensitized to Ova by
intra-peritoneal (IP) injection of 50µg Ova in 200µl 0.9% sterile saline. Twelve days after
sensitization (day 62) mice were challenged IN with Ova (10µg, 50µl PBS, for 4 consecutive
days). One day later (day 5 post Ova challenge), mice were euthanized by sodium pentobarbital
overdose and features of acute airway disease (AAD) were characterized.

Chlamydial Infection
All mice were weighed initially and then daily. The rate of weight gain/loss was calculated (g/d)
over the entire course of the study as an indicator of health status. Chlamydial lung infection was
initially assessed by PCR and organism numbers in the lungs, liver and spleen were determined
tissue culture. Briefly, lung tissues was cut and weighed followed by homogenization in sterile
SPG. Homogenates were centrifuged and the supernatant used for culture and DNA isolation.
Chlamydial organisms were cultured utilizing 24-well plates with 12 mm coverslips
seeded with a semi-confluent monolayer of mouse macrophages (J774A.1) for 36 hours.
Following incubation, cells were fixed and immunostained using Pathfinder antibody (Bio-Rad,
Hercules, CA) according to manufacturer’s instructions and inclusion forming unit counts (IFUs)
were done.
Genomic DNA was isolated from BAL & lung tissue using the QIAMP DNA Blood mini
kit (Qiagen) PCR was used to detect chlamydial DNA. Previously published Ct primers P1 and
Omp2 were used to amplify a 1,130bp fragment (12).
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Bronchoalveolar lavage fluid Lavage (BAL) and Cellularity Analysis
Bronchoalveolar lavage fluid (BAL) was obtained by cannulation of the trachea and lavaging the
airways with 2x 1 ml sterile saline. BAL cell counts were performed with a cell counting
chamber (hemacytometer, improved Neubauer) under phase microscopy with results expressed as
“number of cells per cubic millimeter”. BAL differential counts were performed using Wright
stained cytospin preparations of BAL.

At least 200 cells were counted per slide to obtain

statistically significant counts.

Serum and BAL Antibodies
Serum antibody titer to Chlamydia as well as Ova was evaluated from tail bleeds taken on a
weekly basis and at time of euthanasia. Chlamydia antibody titers were evaluated by enzyme
linked ImmunoSorbent assay (ELISA). The ELISA wells were coated with purified chlamydial
EBs (300 ug/ml) and serial dilutions of each mouse serum added. Following the required washes,
bound primary antibodies were detected by an AP-conjugated goat anti-mouse secondary
antibody. Quantitative assessment of OVA-IgE in the BAL fluid and serum was conducted using
OVA-specific mouse-IgE ELISA kit from BD Biosciences, according to the manufacturer’s
instructions. Chlamydia specific IgE antibodies were detected using Western blot assay as
previously described (15, 16)

Cytokine Production in BAL
Total cytokines secreted in the lung milieu was determined through analysis of BAL fluid.
Concentrations of IL-2, IL-4, IL-5, IL-12, IL-13, and IFN-γ were determined using OptEIA
Mouse ELISA kits (BD Biosciences) according to manufacturer’s instructions.
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Cytokine Production in WBCs from Lymph Nodes
Upon euthanasia, mediastinal lymph nodes were collected from each mouse, pooled in pairs and
homogenized by forcing them through cell sieves. The cells were pelleted and resuspended in
RBC lysing buffer, followed by another centrifuge step and resuspension in DMEM culture
media containing 5% FBS. Cell numbers were determined by counting on a hemocytometer and
approximately 2 x 106 cells/ml were used to seed 24-well plates and were then stimulated with
Ova, formalin killed Chlamydia, J774A.1 cell lysates, or PBS. Supernatant was removed at 12h
intervals over a 72h time period and frozen until time of testing. These supernatants were
evaluated for production of IL-2, IL-4, IL-5, IL-12, IL-13 and IFN-γ using the BD Bioscience kit
described in the previous section.

Statistics: Mice were evaluated in groups of 4. Results are presented as mean± SEM from each
test and control group of mice. All analyses were performed using the SPSS Graduate Pack 11 for
Windows and significant associations or differences are based on two tailed tests with p values
<0.05.

RT PCR
Messenger RNA was isolated from lung tissue using Trizol extraction.

RT-PCR was used to

determine expression of mRNA for CD23, IgE heavy chain, histidine decarboxylase (HDC),
CD40L, and FcεRI alpha, beta, and gamma using previously published primers (7).

Results
Chlamydial Lung Infection and Associated Pathology
The OVA sensitization model of asthma is widely used and well characterized displaying
features very similar to those seen in human allergic asthma. We performed intranasal inoculation
of the chlamydial organism or control in each of our mouse groups as described in the methods
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section and assessed the course of infection-related pathology as well as changes associated
specifically with the induction of bronchial inflammation and airway hyperresponsiveness
following Ova sensitization and challenge. Animals were weighted each day and the weight trend
shows significant weight loss in Chlamydia-infected vs. uninfected adult mice starting at four
days post infection. The most significant differences in weight gain were observed in neonates
between days 32 and 52, where on average infected neonatal mice were 28% (6.1g) smaller than
uninfected neonates (Figure 17B). In adults the most significant weight loss was between days 8
and 28, where on average infected adults were 26% (5.9g) smaller than their uninfected counter
parts (Figure 17A). However, the rate of weight gain between infected and uninfected adult
groups was not significantly different during the later parts of the time course (Figure 17A).
Infected neonatal mice, however, demonstrated retarded weight gain throughout the course of the
study compared to uninfected neonates (Figure 17B) at an IFU of 200.
In an effort to assess the humoral immune response to intranasal chlamydial challenge,
we collected sera from each animal on a weekly basis and assayed for anti-Chlamydia antibody
response. The data revealed strong antibody responses to Chlamydia infection in the adult mice.
Neonatal animals whose immune system was not yet fully developed had an attenuated antibody
response initially, but the response continued to increase for the duration of the study (Figure 18).
Titers began to decrease in infected adult animals around the time of infection clearance; however
infected neonatal mice did not clear the infection, explaining why the titers consistently increased
over the course of the study.
The concentration of chlamydial organism in the lungs (IFU/mg) of neonatal animals
increased significantly with time and there was almost a 2 fold increase from day 14to day 66
(Figure 19). In contrast, infected adults never had significant increases in chlamydial IFU/mg
during the course of the study, and ultimately cleared the infection 28 days pi. By day 7,
chlamydial organisms could be found in the liver, spleen and peripheral blood (tail bleeds),
demonstrating dissemination from the respiratory mucosa and leading to systemic infection.
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WBC and Cytokine Response to Respiratory Chlamydial Infection
It is well established that genital chlamydia infection induces a Th1 immune response
characterized by IFN-γ secretion and that this type of response is essential for clearance of this
intracellular pathogen. It is also well documented that AAD is a Th2-driven disease characterized
by the influx of Th2 cytokines, eosinophils and allergic hyperresponsiveness. We therefore
sought to determine what would characterize lung infection with Chlamydia. BAL fluid was
analyzed for the presence of Th1 and Th2 cytokines using BD Biosciences cytokine kits. The data
confirmed that infected adults secreted significantly elevated amounts of Th1 cytokines (IFN-γ
and IL-2) compared to uninfected animals (Figure 21A and B). However, infected neonates
responded to chlamydial infection with a robust Th2 cytokine response (IL-4, IL-10, IL-5, and
IL-13) compared to their compared to their uninfected and adult infected counterparts (Figure
21C-F). Infected neonatal mice had significantly elevated IL-4 and IL-10 production compared to
infected adults 28 days post infection (P=0.0248, 0.0434 respectively). Mediastinal lymph node T
cells from infected adult and neonatal mice were also isolated, cultured and stimulated with
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Figure 17: Adult and neonatal weight trends
Weight trend graphs show significant weight loss in Chlamydia infected adults vs. uninfected
adults between days 8 and 28 post infection (on average 5.9g smaller (26%)). However, infected
adults recovered lost weight by day 44 (A). Infected neonatal mice showed retarded weight gain
throughout the course of the study compared to uninfected neonates but the most significant
differences could be seen between days 32 and 52 (on average 6.1g smaller (28%)) (B).
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Figure 18: Chlamydia antibody titers over time
Antibody titer graph shows strong antibody responses to Chlamydia from infected adult mice but
relatively decreased and /or retarded antibody titers in the infected neonatal mouse groups.
Infected adult titers dropped once infections cleared, however infected neonatal mice did not clear
the infection and their titers consistently increased over the course of the study.
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Figure 19: Cultured chlamydial carriage/concentration in the lungs
Infected adult mice were able to clear the chlamydial infection after day 28. Infected neonates
were unable to clear the chlamydial infection during the course of this study and chlamydial
concentration per/mg of tissue as well as total chlamydial carriage in lung continued increase over
time.
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Figure 20: BAL cellularity during chlamydial infection
Elevated total WBCs and neutrophil levels were seen in infected neonatal and adult groups (A,
C). Infected adults had elevated macrophage/monocytes, whereas infected neonates were
characterized by significantly elevated eosinophil levels on day 28 pi compared to uninfected
adults (P=0.0449, panel D).
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Figure 21: BAL cytokines during chlamydial infection
Infected adults displayed a more pronounced Th1 cytokine response (IFN-γ and IL-2) than
infected neonates (A, B). Infected neonates responded to chlamydial infection with a robust Th2
cytokine response (IL-4, IL-10, IL-5, and IL-13) compared to their adult counterparts (C-F).
Specifically, neonatal mice produced significantly elevated levels of IL-4 compared to infected
adults 14 and 28 days post infection (P=0.0312, 0.0248 respectively, D) as well as IL-10 28 days
post infection (P=0.0434 E).
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purified chlamydial elementary bodies to assess T- cell specific cytokine production. The
cytokine profiles were identical to that seen in the BAL fluid, clearly highlighting the contrasting
Th1 cytokine production seen in adult animals compared to the Th2 cytokine profile elicited by
neonatal respiratory chlamydial infection (Figure 6). Specifically, neonatal mice had significantly
more IL-5 and IL-4 cytokine production in response to chlamydial antigen (P=0.0456, 0.0444
respectively (Figure 22C, D). The magnitude of cytokine response in the tissue culture fluid from
draining lymph node T cells was significantly greater than that seen in the BAL fluid.
The robust cytokine response in the airway of Chlamydia-infected adults and neonatal
mice was complemented by the accumulation of predominantly macrophages (9.7x102) and
neutrophils (8.3x103) in the BAL fluid of adult mice 28 days post infection, along with markedly
less eosinophils (1.5x102). In contrast, 28 days pi infected neonatal mice presented with
significantly elevated eosinophils (9.7x102, P=0.0449) compared to infected adults. There was no
significant difference in infected neonatal BAL neutrophils (6.8x103), or macrophages (2.1x102)
compared to infected adults (Figure 20 A-D), however infected groups had significantly elevated
levels of all cell types when compared to uninfected controls. This highlights a major difference
in the early life response of mice to chlamydial infection compared to adult counterparts.

Cellular and Cytokine Response to Induction of Allergic Airway Disease in Neonatal and
Adult Mice
Having established that early life chlamydial infection induces different responses in
neonatal compared to adult mice, we wanted to further determine if induction of allergic airway
disease had different cytokine and cellular profiles as well. In this model, following respiratory
infection with Chlamydia, mice were sensitized to Ova and some groups were challenged over
several days while others remained unchallenged for comparison(Table 12).Our infected neonatal
group (group 3 neonate) who still had active infections, and no AAD presented with significantly
elevated numbers of total white blood cells, neutrophils and eosinophils, but only background
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Figure 22: Mediastinal lymph node cell stimulation during chlamydial Infection.
WBCs harvested from mediastinal lymph nodes were stimulated with heat killed chlamydial
antigen and resulting cytokine secretions revealed that cells from infected adult mice secreted
elevated levels of IFN-g and IL-2 when compared to infected neonates and controls (A, B).
Cells harvested from infected neonatal mice secreted predominantly Th2 (IL-5, 4, 10, and 13)
cytokines in response to chlamydial antigen compared to infected adults and control groups (CF). WBCs from infected neonatal mice 14 days and 28 days post infection produced significantly
elevated levels of IL-5 (P=0.0353, 0.0456 respectively, C) and IL-4 (P=0.0444, D) when
compared to WBCs from infected adults. Cells were also stimulated with PBS and J774A.1
proteins as controls (data not shown).
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Neonatal & Adult Groups
Description of Treatment
Group 1
Infected, Sensitized with Ova & Challenged
Group 2
Uninfected, Sensitized with Ova & Challenged
Group 3
Infected, No Sensitization & No Challenge
Table 12: Animal grouping and treatments
Sensitization and subsequent challenge with ovalbumin is required to induce allergic airway
disease.
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numbers of monocyte/macrophage cells when compared to their infected adult counterparts
(group 3 adults) who did not have active infections (P=0.0001, 0.0003, and 0.0004 respectively,
Figure 23A-D). Indeed all groups which had allergic airway disease induced (see table 12) had
airways characterized by elevated levels of BAL eosinophils; however, infected neonates who did
not have AAD induced, had comparable levels of eosinophils in their BAL fluid to the AAD
induced groups, suggesting that chlamydial infection plus challenge with Ova results in elevated
eosinophils. The most significant elevation in eosinophils, however, was seen in neonatal animals
that had active infections and AAD induced (Figure 23D). There was no significant increase in
BAL macrophage/monocytes in any treatment group.
BAL and mediastinal lymph node cytokine production in AAD induced animals was also
assessed. Infected neonatal animals demonstrated a significant increase in the production of BAL
Th2 cytokines (IL-4, -5, -10 and -13) in response to Ova challenge and sensitization, but also
responded with the production Th1 cytokines (IFN-γ and IL-2) compared to their adult or
uninfected counterparts (Figure 24). Indeed, there was no statistical difference in the level of
cytokines produced by infected neonatal mice that were not sensitized but later challenged with
Ova (Group 3 Neonates vs. Group 1 Neonates in graphs, see table 1) when compared to the
infected, sensitized and challenged group, suggesting that these animals might have become
hyperresponsive as a result of early life chlamydial infection. In contrast, Group 3 neonates with
active infections and no AAD produced significantly elevated levels of IFN-g, IL-5, and IL-4
when compared to group 3 adults which had cleared infections and no AAD(P=0.0092, 0.0362,
and 0.0092 respectively, Figure 24A, C, D).

Though not significant, these neonates also

presented with elevated IL-2, IL-10, and IL-13 when compared to adult mice, showing that
chlamydial infection alone was able to elicit a Th1/Th2 cytokine response.
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Figure 23: BAL cellularity during allergic airway disease
Infected neonatal groups with active infections had elevated levels of total WBCs, neutrophils,
and eosinophils compared to all other groups (A, C, D). All groups which had allergic airway
induced (AAD) with Ova had elevated levels of BAL eosinophils; however group 3 neonates who
had active infections but did not have AAD induced had significantly elevated levels of BAL
WBCs, neutrophils, and eosinophils when compared to their adult counter parts (P=0.0001,
0.0003, and 0.0004 respectively); group 1 neonates who had active infections and AAD induced
had enhanced levels of BAL WBCs, neutrophils, and eosinophils when compared to all other
groups (A, C, D). There was no significant increase in BAL macrophage/monocytes in any
group (B).
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Figure 24: BAL cytokines during allergic airway disease
Infected adults, who cleared infection, developed a mixed Th1/Th2 immune response during
allergic airway induction (C-F). Group 1 and 3 infected neonates responded with a significant
increase in IFN-g (P=0.0049, 0.0092 respectively, A) and elevated levels of IL-2 when compared
to corresponding adult groups (B). Th2 cytokines that were produced in all groups that had AAD
induced (C-F). Infected neonates hyper reacted to ovalbumin compared to their adult and
uninfected counterparts. Importantly to note, group 3 neonates who had active infections but no
AAD produced significantly elevated amounts of IL-5 and IL-4 (P=0.0152, 0.0362 respectively
C, D) and elevated levels of IL-10, and 13 compared to all other groups (E, F). Collectively, the
data therefore suggests that early life chlamydial infection induces an allergic airway response
upon allergen challenge that is typical of asthma pathogenesis and supports a chronic infection
model airway hyperresponsiveness.
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Mediastinal Lymph Node T cell-specific Cytokine Response to Chlamydia and Ova
Stimulation
To assess and confirm the specific immunological response to Ova stimulation,
mediastinal lymph node T cells were cultured as previously described for assessment of
Chlamydia and Ova antigen specific cytokine. Ova-specific T cells from all Ova sensitized and
challenged adult and neonatal animals produced significant levels of IL-4, -5, -10 and -13 in
response to Ova stimulation in vitro (Figure 26 C-F). However, there was no production of the
Th1- specific cytokines, IL-2 and IFN-γ (Figure 26 A & B). This was accompanied by a
significant increase in the production of Ova-specific IgE antibodies in both the serum and BAL
fluid of all sensitized and challenged groups (Figure 27). Mediastinal lymph node T cells from
all Chlamydia-infected neonatal groups released significantly elevated levels of IL-2, -4, -5, -10, 13, and IFN-γ in response to chlamydial antigen when compared to controls (Figure 25). By
contrast, mediastinal lymph node T cells from similarly treated adult mice produced no
significant levels of Th2 cytokines (IL-4, -5, -10 and -13), and much lower levels of IL-2 or IFNγ when compared to similarly treated neonatal animals. As controls, cells were also stimulated
with cell lysate and sterile saline, resulting in no cytokine production. In addition, only infected
neonatal mice produced Chlamydia-specific IgE antibodies when compared to all other groups.
The level and antigen specificity of Chlamydia-specific IgE antibodies increased significantly
over time as demonstrated by the band intensity and diversity on the Western blot image (Figure
28). Moreover, only approximately 6 chlamydial antigens appear to induce IgE production in this
model,

including

the

40kDa

major

outer

membrane

protein

(Momp),

chlamydial

lipopolysaccharide (cLPS at 4-6kDa), the Chlamydia lectin binding proteins (LBP, 18 and
27kDa) and the cysteine rich protein A (CrpA, 15kDa). Infected adult animals demonstrated no
Chlamydia-specific IgE in their sera, even at the time of sacrifice.
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Figure 25: Mediastinal lymph node cell stimulation during allergic airway disease
WBCs harvested from mediastinal lymph nodes were stimulated as described previously
described (Figure 5). Stimulation revealed that cells from infected neonatal mice with active
infections (Groups 1 and 3) secreted elevated levels of IFN-g and IL-2 when compared to
infected adults and controls (A, B). Cells harvested from infected neonatal mice secreted
predominantly Th2 (IL-5, 4, 10, and 13) cytokines in response to chlamydial antigen compared to
infected adults and control groups (C-F). Infected neonates with AAD (group 1) produced
significantly more IL-5, IL-4, and IL-13 compared to corresponding adult groups (P=0.0302,
0.0437, and 0.0362 respectively C, D, F). Infected neonates which did not have AAD were also
able to produce significantly elevated levels of IL-4 and IL-13 compared to adults groups as well
(P=0.0456, 0.0075 respectively C, F). Cells were also stimulated with PBS and J774A.1 proteins
as controls (data not shown).
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Figure 26: Mediastinal lymph node cell stimulation with OVA
WBCs harvested from mediastinal lymph nodes were stimulated as described previously
described but ovalbumin was used instead of heat killed chlamydial organisms. Stimulation
revealed that cells from groups 1 and 2 that were sensitized and challenged with ova secreted
predominantly Th2 (IL-5, 4, 10, and 13) cytokines in response to ova antigen compared to
unsensitized/challenged control groups (C-F). Th1 cytokines (IFN-g, IL-2) were produced in
negligible amounts in response to ova stimulation (A, B).
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Figure 27: BAL Ova-Specific IgE during Allergic Airway Induction
Allergic airways were induced using ovalbumin. Groups which were both sensitized and
challenged with ova had significantly elevated levels of ova-specific IgE antibodies present in
BAL fluid (A) and serum (B), demonstrating successful allergic airway induction. Although not
significant, infected neonatal group produced more ova-IgE than comparable adult group (Group
1).
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Figure 28: Detection of Chlamydia Specific IgE
Western Blot analysis revealed the presence of Chlamydia-specific IgE antibodies in the BAL
fluid of infected neonatal groups only. Antibodies appeared as early as 28 days post infection and
were still detectable 66 days post infection. Chlamydia-specific IgE antibodies appear to have
been generated against a variety of chlamydial antigen representing a total of approximately 6
proteins. All proteins that induced IgE were either secreted or surface exposed.
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Duration of Effects of Infection on AAD
Neonatal respiratory infection with Chlamydia resulted in chronic infection of lungs with
increased infiltration over time. Chlamydia became systemic with time leading to increased
bacteria load in the liver and spleen by day 14. While infected adult animals cleared the infection
after day 42, neonatal mice remained infected for the duration of the study. However, these
infected neonatal animals did not demonstrate overt physiologic signs of this infection and
respiratory distress was not increased over time, although levels of both Th1 and Th2 cytokines
remained elevated at 5 days after the last Ova challenge.

mRNA Expression of Histidine decarboxylase, IgE and its High – and Low – Affinity
Receptors
Neonatal lung infection with Chlamydia resulted in significant induction of mRNA
expression for IgE and its high- (FcεR1α,β,γ) and low- (CD23) affinity receptors, while infected
adult controls did not. There was a concomitant increase in Th2 regulatory cytokine secretion (IL4, -5, -10, and -13) in BAL and serum of neonatal mice, while adult mice secreted Th1 cytokines
(IL-2, IFN-γ) in response to airway infection (Figure 29). mRNA expression of HDC, the only
rate-limiting enzyme that catalyzes the formation of histamine from L-histidine, along with
CD40L, were also significantly increased in infected neonates compared to controls. While
infected adult mice cleared the infection by day 30, neonates never cleared the infection and
secreted Chlamydia-specific IgE in both serum and BAL. Ova sensitization and subsequent
challenge significantly increased mRNA expression of these allergic markers along with cytokine
secretion in the mouse airway (Figure 30).
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Figure 29: Characterization of chlamydial infection in neonatal and adult mice
Neonatal lung infection with Chlamydia resulted in significant induction of mRNA expression for
IgE and its high- (FcεR1α, β and γ) and low- (CD23) affinity receptors, while infected adult
controls did not. mRNA expression of HDC, the only rate-limiting enzyme that catalyzes the
formation of histamine from L-histidine, along with CD40L (primarily expressed on the surface
of activated T-cells leading to B-cell proliferation), were also significantly increased in infected
neonates compared to uninfected controls.
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Figure 30: Characterization of chlamydial infection in neonatal and adult mice during
allergic airway disease
Ova sensitization and subsequent challenge significantly increased mRNA expression of allergic
markers along with cytokine secretion in the airways of mice that were sensitized and challenged
with Ova. Infected neonatal mice that had not cleared infections 66 days p.i. expressed the
highest levels of allergic mRNA markers. Ova sensitization and challenge enhanced expression
of these markers in infected neonatal but not adult mice.
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Discussion
Asthma is a major public health problem and remains a significant burden on families
and society in general. The most recent asthma surveillance data from the Centers for Disease
Control and Prevention (CDC) report that asthma cost our nation $56 billion each year and that 1
in 11 American children have the disease (17). Asthma is the most common chronic disease of
childhood and the numbers of young people and children with asthma continues to rise. While
many cases of asthma are successfully managed and patients lead a relatively normal life, there is
no cure for the disease and a growing number of severe, persistent asthmatics present with a
phenotype that is refractive to oral or inhaled corticosteroid treatment. New reports confirm that
patients with severe refractory asthma have the greatest unmet treatment needs to improve asthma
control and reduce exacerbation risk (18). In order to effectively treat, especially children with
refractory asthma, it is necessary to better understand the etiology and or mechanisms involved in
the development childhood asthma. Previous studies demonstrated that early-life respiratory viral
infections, specifically with respiratory syncytial virus (RSV), increased the risk of subsequent
development of childhood asthma (19). In the model reported in the that study, allergic airway
inflammation, characterized by eosinophil recruitment and Th2 cytokine infiltration was
prominent only in animals that had recovered from neonatal infection with pneumonia virus of
mice and then later sensitized and chronically challenged with antigen (19).
In the current study we sought to better understand the underlying immunological
mechanisms involved in the development of childhood asthma. We have demonstrated that while
chlamydial organisms typically induce a Th1 type cytokine response with corresponding
macrophage and neutrophil infiltration, neonatal respiratory infection led to production of Th2
dominant cytokines and infiltration of neutrophils and eosinophils in the airway. These results are
similar to those previously reported by Horvat et al (14) using a similar Ova mouse model. In the
current study however, we also demonstrated prolonged infection in neonatal animals that never
cleared the bacteria from their lungs over the entire course of the study. While we utilized twice
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the inoculum (200 IFU) used by Horvet et al, this inoculum still represents less than what would
typically be found in a single chlamydial inclusion, that can hold between 500 to 1000 EBs (20).
Mediastinal lymph node T cells and BAL fluid revealed a significant increase in Th1 and
Th2 cytokines upon Ova sensitization and challenge in neonatal animals, but to a significantly
less extent in adult animals who produced no Th2 cytokines upon Ova sensitization and
challenge. Indeed the levels of Th2 cytokines seen in neonatal animals that were infected and
challenged without Ova sensitization were essentially similar to those of infected neonates who
were both sensitized and later challenged with Ova. These data suggest that adult animals
infected with Chlamydia in early life, display a hyperresponsive airway and a predisposition to
allergic inflammatory diseases later in life. This hypothesis is supported by studies done by You,
et al, demonstrating that severe RSV infection during neonatal development significantly altered
lung structure and the pulmonary immune micro-environment, which could potentially increase
the risk of airway hyperresponsiveness later in life (21).
Neonatal mice never cleared the chlamydial organisms from their lungs and the bacteria
disseminated to the liver and spleen and could also be isolated from the peripheral blood starting
at 7days post infection and at the time of euthanasia. This study also confirmed that mice infected
as neonates but not adults, produced and released Chlamydia-specific IgE antibodies in both the
serum and BAL fluid, while the adult mice did not.
The data have important implications in asthma development and potential treatment or
intervention for early-life respiratory infection. In a recent report by Seigle et al, the authors
utilized a murine model of childhood asthma to demonstrate the utility of administration of antiIL-4 or anti-IL-25 (22). These antibodies prevented development of some key features of asthma,
suggesting that suppression of a Th2 response during the neonatal period or later in childhood
could be effective for preventing later chronic severe disease(22).
We therefore conclude that chlamydial airway infection early in development, can lead to
significant alteration in lung structure and the immune architecture of the respiratory micro119

environment. Early life Chlamydia infection was not cleared in this model, suggesting that this
type of structural airway damage and immune modulation through continued secretion of Th2
cytokines continued unabated. Upon allergen exposure, the interaction between early-life
chlamydial infection which results in chronic pulmonary inflammation and allergen sensitization
exacerbates allergic airway disease through increased cytokine secretion and cellular infiltration.
This combination has the potential to lead to more severe asthma that is refractory to inhaled
steroids, since the root of the initial inflammation is a pathogen and could still be lurking in the
lung tissue.
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CHAPTER 6
THE ROLE OF HEPOXILINS AND HISTAMINE PRODUCING NEUTROPHILS IN
INFECTIOUS ASTHMA
Abstract
Rationale: Hepoxilins are biologically active metabolites of arachidonic acid that are formed
through the 12-lipoxygenase pathway. Hepoxilins were recently identified as potent neutrophil
chemoattractants in the intestinal mucosa, playing an even greater role than IL-8. Our goals in
this study is to determine if C. pneumoniae infection of the airways of asthmatics induces the
release of hepoxilins, to determine if hepoxilin is a neutrophil chemoattractant in the airway, and
finally, to determine if these neutrophils produce histamine in response to C. pneumoniae
infection.
Purpose: To determine if neutrophils, provoked by C. pneumoniae-induced lung infection,
undergo transmigration through an IL-8/hepoxilin gradient and greatly expand their capacity to
synthesize histamine, thereby contributing to airway inflammation and pathology.
Methods: Adult (4 wks) BALB/c mice were infected intranasally with Chlamydia (MoPn) and 4
weeks later were sensitized and challenged with ovalbumin. Allergic airway disease (AAD) was
characterized by examination of serum and bronchoalveolar lavage fluid (BAL) cellularity,
cytokine production and antibody response. The presence of Chlamydia was determined by PCR
and culture. We further assessed AAD by evaluating the expression of mRNA for histidine
decarboxylase (HDC) in lung tissue and in purified BAL neutrophils. Hepoxilin production was
assessed via Western blot using antibodies specific to 12-lipoxygenase precursor (12-LO).
Results: Chlamydial infection in mice induced increased production of Th1 cytokines (IL-2, IL12, TNF-a, IFN-γ) in BAL compared to uninfected mice. Infected mice responded to chlamydial
infection with robust neutrophil infiltration. When allergic airway was induced using ovalbumin,
AAD induced mice increased their production of IL-4, IL-5 and IL-13 by >3 fold compared to
unsensitized groups. In addition, 12-LO mRNA is up regulated in mice infected with Chlamydia,
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but not in uninfected AAD mice. Histidine Decarboxylase (HDC) mRNA expression is increased
in BAL neutrophils of Chlamydia infected mice, but was not in AAD induced only or uninfected
mice.
Conclusions: Our data indicates histamine is produced by BAL neutrophils in response to
chlamydial infection and Chlamydia elicits 12-LO production which can induce neutrophil
infiltration.

Introduction
Asthma is a multifactorial disease characterized by recurrent cough, wheezing, chest
tightness or shortness of breath, leading to airway inflammation. Approximately 34.1 million
Americans have been diagnosed with asthma by a health professional during their lifetime (1).
Several types of cells are involved in the pathophysiology of asthma. The contribution of mast
cells, lymphocytes, and eosinophils has been well established. Although eosinophilic airway
inflammation is recognized as an important feature of some patients with chronic, stable asthma,
evidence supports an important role for neutrophils in asthma (2). Neutrophils are
polymorphonuclear leukocytes that play an essential role in the immune system, acting as the first
line of defense against bacterial and fungal infections. Their role in the inflammatory process was
once thought to be restricted to phagocytosis and the release of enzymes and other cytotoxic
agents, but it is now known that these are the first cells recruited to the site of allergic reaction
and can release diverse mediators that have profound effects on the airways of asthmatic
individuals (3). Their presence may therefore influence clinical presentation and has been linked
to the development of severe chronic asthma and sudden severe attacks (3). Moreover, a review
of the literature found that only around 50% of asthma cases were associated with eosinophilic
inflammation, and that in most other cases asthma was accompanied by an increase in airway
neutrophils (3). Bacterial infections at epithelial surfaces, such as those that line the gut and the
lung, stimulate the migration of neutrophils through the coordinated actions of chemoattractants
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secreted from pathogen-stimulated epithelial cells (4-6). IL-8 has been shown to stimulate
neutrophils to leave the bloodstream at a local site of mucosal inflammation. However,
basolateral IL-8 release is insufficient to induce the migration of neutrophils across the intestinal
epithelium, suggesting that the production of other inflammatory mediators, whose release would
probably be polarized apically, are important for the execution of this step in the inflammatory
pathway (7, 8). The chemical gradient used by neutrophils to move between adjacent epithelial
cells and traverse the tight junction at the apical neck of these mucosal barriers has eluded
identification for decades (9). One such factor involved in attracting polymorphonuclear
leukocytes across the epithelium was identified in 2004 by the McCormick group at UMass
Worcester as the eicosanoid, hepoxilin A3 (7).
HepA3 was shown to be selectively secreted from the apical surface of human intestinal
epithelial stimulated with Salmonella enterica serotype Typhimurium (7). Hepoxilins are formed
by a variety of tissues and possess a diversity of actions based on their ability to modulate ion
fluxes, including calcium and potassium ions in the cell (10). More recent studies confirmed that
the hepA3 chemoattractant is a key factor promoting the final step in neutrophil recruitment to
sites of mucosal inflammation (9, 11). The data confirmed that hepA3 is synthesized by epithelial
cells and secreted from their apical surface in response to conditions that stimulate inflammatory
events (9). Once induced, hepA3 acts to draw neutrophils, via the establishment of a gradient
across the epithelial tight junction complex. Disruption of the 12-lipoxygenase pathway (required
for hepA3 production) dramatically reduces neutrophil-mediated tissue damage (7). However, it
has not been definitively determined if hepoxilins and more specifically, hepA3, plays a role in
neutrophil transmigration in the asthmatic lungs or if these cells contribute to AHA in addition to
general inflammation. More importantly, it is not yet clear if specific bacterial and/or viral
pathogens like C. pneumoniae can A) induce the increased release of hepoxilins into the airway
or B) induce the release of histamine from the neutrophils that have recently arrived from the
circulation due to hepoxilin or IL-8 chemotaxis.
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Materials & Methods

Mouse model treatment and sample collection
IACUC approval was obtained through the University of Massachusetts to utilize 4 groups (15
each) of 2 week old mice for this study. Mouse asthma models were generated by sensitizing
Balb/C animals with the 45 kDa egg-white glycoprotein, ovalbumin (OVA) intraperitoneally
followed by several challenges via aerosolization. Group 1 was infected via the airways with C.
muridarum for 14 days and then sensitized and challenged; group 2 was mock infected,
challenged and sensitized with OVA on the same schedule as group 1. This treatment resulted in
a Th-2 response in the lungs, with varying levels of airway responsiveness. Group 3 was
infected, but challenged and sensitized using saline instead of Ova; group 4 was mock-infected
and mock challenged with saline. Animals then had BAL fluid collected and the extent of
hepoxilin release evaluated via measurement of hepA3 at days 7, 14, 28, and 42 when animals
were sacrificed. Five animals from each group were sacrificed at each time point to obtain BAL
fluid, cells and tissue for histology. Lung tissue to be used for RNA extraction was flash frozen in
liquid nitrogen or on dry ice.

Analysis of mouse BAL fluid cellularity and the indirect presence of hepoxilin
Bronchoalveolar lavage fluid (BAL) was obtained by cannulation of the trachea and lavaging the
airways with 2x 1 ml sterile saline. BAL cell counts were performed with a cell counting
chamber (hemacytometer, improved Neubauer) under phase microscopy with results expressed as
“number of cells per cubic millimeter”. BAL differential counts were performed using Wright
stained cytospin preparations of BAL.

At least 200 cells were counted per slide to obtain

statistically significant counts.
In order to determine the presence and quantity of hepoxilin in the lung tissue from the
mouse model, we will utilize Western Blotting which is used routinely used by groups that work
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with hepoxilins (9). With this method, we detected two lipoxygenase (LO) enzymes that
selectively place epoxide structures from a hydroxyl residue positioned at the 5, or 12 carbon of
arachidonic acid or its metabolites, the 5 or 12 carbon have demonstrated any capacity to
stimulate hepA3 production. 12-LO is the precursor for hepoxilin and its presence directly
indicates the presence of hepoxilin.

Antibodies used to detect 5-LO and 12-LO were

commercially produced from purchased from Santa Cruz Biotech (www.scbt.com). We further
confirmed the production of hepA3 by RT-PCR for 5-LO and 12-LO as previously described
utilizing published primers (9).

Isolation of BAL neutrophils and detection of histidine decarboxylase (HDC) mRNA
Cells were isolated from mice as described above and utilized for measurement of overall white
blood cell infiltration and neutrophil population. Neutrophil isolation from BAL was done using
a Mouse Neutrophil Negative Selection Kit from STEMCELL Technologies according to
manufacturer’s instructions. We utilized molecular genetics to determine if neutrophils in C.
pneumoniae infected airways produce and release histamine. Neutrophils were also collected
from mice that have not previously been exposed to Chlamydia. Following isolation RNA
extraction was done using Trizol extraction. Expression of HDC mRNA was determined by RTPCR using previously published primers (1).

Chlamydial infection
All mice were weighed initially and then daily. The rate of weight gain/loss was calculated (g/d)
over the entire course of the study as an indicator of health status. Chlamydial lung infection was
initially assessed by PCR and organism numbers in the lungs, liver and spleen were determined
tissue culture. Briefly, lung tissues was cut and weighed followed by homogenization in sterile
SPG. Homogenates were centrifuged and the supernatant used for culture and DNA isolation.
Chlamydial organisms were cultured utilizing 24-well plates with 12 mm coverslips
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seeded with a semi-confluent monolayer of mouse macrophages (J774A.1) for 36 hours.
Following incubation, cells were fixed and immunostained using Pathfinder antibody (Bio-Rad,
Hercules, CA) according to manufacturer’s instructions and inclusion forming unit counts (IFUs)
were done.
Genomic DNA was isolated from BAL & lung tissue using the QIAMP DNA Blood mini
kit (Qiagen) PCR was used to detect chlamydial DNA. Previously published Ct primers P1 and
Omp2 were used to amplify a 1,130bp fragment (12).

Serum and BAL antibodies
Serum antibody titer to Chlamydia as well as Ova was evaluated from tail bleeds taken on a
weekly basis and at time of euthanasia. Chlamydia antibody titers were evaluated by enzyme
linked ImmunoSorbent assay (ELISA). The ELISA wells were coated with purified chlamydial
EBs (300 ug/ml) and serial dilutions of each mouse serum added. Following the required washes,
bound primary antibodies were detected by an AP-conjugated goat anti-mouse secondary
antibody. Quantitative assessment of OVA-IgE in the BAL fluid and serum was conducted using
OVA-specific mouse-IgE ELISA kit from BD Biosciences, according to the manufacturer’s
instructions. Chlamydia specific IgE antibodies were detected using Western blot assay as
previously described.

Cytokine production in BAL
Total cytokines secreted in the lung milieu was determined through analysis of BAL fluid.
Concentrations of IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17A, IL-23, TNF-a, TGFB1, and
IFN-γ were determined using Multi-Analyte ELISArray Kits (Mouse Th1/Th2/Th17 Cytokines)
(SABiosciences) according to manufacturer’s instructions.

Statistical Analysis
128

Mice were evaluated in groups of 5. Results are presented as mean± SEM from each test
and control group of mice. Analyses were performed using the SPSS Graduate Pack 11 for
Windows and associations or differences are based on two tailed tests with p values <0.05.

Results
Chlamydial Lung Infection and Associated Pathology
Animals were weighed each day and the weight trend shows significant weight loss in
Chlamydia-infected vs. uninfected mice starting at four days post infection. The most significant
differences in weight gain were observed in adults between days 16 and 32, where on average
infected mice were 30% (5.7g) smaller than uninfected mice. However, the rate of weight gain
between infected and uninfected adult groups was not significantly different during the later parts
of the time course (Figure 31).
To assess the humoral immune response to intranasal chlamydial challenge, sera weekly
collected from each animal was assayed for anti-Chlamydia antibody titers. The data revealed
strong antibody responses to Chlamydia infection in infected mice (Figure 32). Titers began to
decrease in infected animals around the time of infection clearance (28-42 days pi).
The concentration of chlamydial organism in the lungs (IFU/mg) of infected animals
increased significantly with time and there was almost a 2 fold increase from day 7 to 14 (Figure
33). However, total carriage began to drop after day 14 and infected animals ultimately cleared
the infection by 42 pi.
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Figure 31: Adult weight trends
Weight trend graphs show weight loss in Chlamydia infected animals vs. uninfected animals
between days 6 and 32 post infection (on average 5.7g smaller (30%). However, infected adults
recovered lost weight by day 42. Error bars represent variation in animal weights within each
group.
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Figure 32: Chlamydia antibody titers over time
Antibody titer graph shows strong antibody responses to Chlamydia from infected animals but
little to no antibody production in uninfected groups. Infected animals titers to Chlamydia began
to drop once infections cleared.
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Figure 33: Cultured chlamydial carriage/concentration in the lungs
Chlamydial carriage in the lung peaked 14 days pi. Chlamydial organisms could not be detected
in the lung 42 days pi. Uninfected animals had no carriage of chlamydial organisms.
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WBC and Cytokine Response to Respiratory Chlamydial Infection and AAD
Typically Chlamydia infection induces a Th1 immune response characterized by IFN-γ secretion
and that this type of response is necessary for clearance. In addition AAD is a Th2-driven disease
characterized by the influx of Th2 cytokines, eosinophils and allergic hyperresponsiveness. In
this study we characterized lung infection with Chlamydia. BAL fluid was analyzed for the
presence of Th1 and Th2 cytokines using SABiosciences cytokine kits. In this model, following
respiratory infection with Chlamydia, mice were sensitized to Ova and some groups were
challenged over several days while others remained unchallenged for comparison (Table 13). The
data confirmed that infected animals secreted significantly elevated amounts of Th1 cytokines
(IFN-γ, TNF-a, IL-2, and IL-12) compared to uninfected animals (Figure 34). Th1 cytokine
levels peaked on days 14 and 28 and dropped off by 42 once infections had cleared. Animals
which were AAD induced responded to ovalbumin with a robust Th2 cytokine response (IL-4,
IL-5, and IL-13) compared to their compared to their uninduced counterparts (Figure 35). Th17
cytokines (IL-17A, IL-23) were also elevated as well and peaked at days 14 and 28 in infected
animals (Figure 36). Uninfected AAD induced animals had negligible levels of Th1 and Th17
cytokine production. IL-10 levels increased in infected and AAD induced animals, TGF-B1 and
IL-6 were not significantly produced in any group (Figure 37).
The robust cytokine response in the airway of Chlamydia-infected only mice (Group 2)
was complemented by the accumulation of predominantly macrophages (9.0x102) and neutrophils
(9.9x103) in the BAL fluid of infected mice 28 days pi, along with markedly less eosinophils
(1.9x102) (Figure 38). In contrast, 28 days pi AAD induced animals presented with significantly
elevated eosinophils (3.6x102) compared to uninduced mice (Figure 37A-D). Mice that were
both AAD induced and infected (Group 1) had slightly elevated levels of all cell types 28 days pi
compared to AAD only groups (Group 3), but was not significant.
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Table 13: Animal grouping and treatments
Sensitization and subsequent challenge with ovalbumin is required to induce allergic airway
disease.
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Figure 34: Th1 cytokine levels during chlamydial infection and AAD induction
Infected animals displayed a robust Th1 cytokine response (IFN-γ, IL-2, IL-12, TNF-a, A-D
respecitively ) in response to chlamydial infection. Infected mice cleared the infection after 28
days. Uninfected and AAD induced only animals produced little to no Th1 cytokines. Th1
cytokine production dropped off by day 42, at the same time infections began to clear in infected
animals.
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Figure 35: Th2 cytokine levels during chlamydial infection and AAD induction
All AAD induced animals developed a Th2 immune response during allergic airway induction
with ovalbumin (A-C). AAD induced mice with active infections produced slightly less Th2
cytokines than their uninfected AAD induced counter parts. Animals that were not AAD induced
did not produce any significant amounts of Th2 cytokines. Th2 cytokine production dropped off
by day 42 once AAD induction was removed.
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Figure 36: Th17 cytokine levels during chlamydial infection and AAD induction
Infected animals displayed a moderate Th17 cytokine response (IL-17A and IL-23) in response to
chlamydial infection (A, B). However, little to no IL-6 was seen in any animal group (C). IL17A and IL-23 levels diminished once chlamydial infections were cleared. Uninfected and AAD
induced only animals produced little to no Th17 cytokines.
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Figure 37: Regulatory T-cell cytokine levels during chlamydial infection and AAD induction
No significant amounts of TGF-B1 were produced in any animal group (A). IL-10 was produced
at significant levels at days 7 and 14 in infected animals. IL-10 continued to be produced at high
levels in infected animals on day 28 but was also produced in AAD induced animals as well.
When AAD induction was removed and infections were cleared IL-10 levels dropped off (B).
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Figure 38: BAL cellularity during allergic airway disease
Infected groups with active infections had elevated levels of total WBCs, neutrophils, and
macrophages compared to all other groups, which peaked on day 28 pi (A, C, D). All groups
which had allergic airway induced (AAD) with Ova had elevated levels of BAL eosinophils on
day 28 (when AAD was fully induced). All cell counts diminished after infections were cleared
and AAD subsided.
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Assessment of hepoxilin production in lung tissue
In order to determine the presence of hepoxilin in the lung tissue from the mouse model,
we utilized Western blotting with specific antibodies in order to detect a hepA3 precursor, 12
lipoxygenase; we also sought to detect 5 lipoxygenase as well, which is a leukotriene precursor.
With this method, we were able to indirectly detect low volumes of hepoxilin; hepoxilin itself has
an extremely short half-life so direct detection is not possible. Western blotting revealed 12-LO
was only detected in infected mouse groups as early as day 7 and until day 28 (Figure 39A). 12LO was not detected in uninfected animals or AAD only groups. 5-LO, the leukotriene precursor,
was detected in infected groups as well as AAD induced groups, as expected (Figure 39B).
In addition, we examined the lung tissue for HDC, 5-LO and 12-LO mRNA expression
using RT-PCR. The data corresponded with our Western Blotting results. 12-LO mRNA was
upregulated only in infected animals, and undetectable in AAD only or uninfected animals
(Figure 40A). 5-LO expression was upregulated in infected animals and AAD induced groups
(Figure 40A). Interestingly, HDC mRNA was upregulated as expected in AAD induced groups,
but was also detected in infected animals which were not AAD induced (Figure 40A).
Expression of 5-LO and 12-LO was seen as early as day 7 until 28, HDC was seen in infected
groups from days 7-28 but was not seen in AAD only groups until day 28 (AAD was established).
By day 42 no expression of 5-LO, 12-LO, or HDC was detected as a result of bacterial clearance
and alleviation of AAD (Figure 40B). Our results indicate that chlamydial infection alone is able
to induce 12-LO expression (ultimately hepoxilin) as well as induce HDC expression (histamine)
in lung tissue.
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Figure 39: 5-LO and 12-LO Western Blot of mouse lung tissue
12-LO (76kDa) protein could be detected using Western Blot only in infected animals from days
7-28, it was not detected in the AAD only or in uninfected animals (A). 12-LO protein was
undetectable on day 42 once the infections had cleared. 5-LO (79kDa) protein was detected in
infected animals on days 7-28, it was also detected in AAD induced animals only on day 28 (day
of induction) (B). 5-LO protein was no longer expressed once AAD and bacterial infections had
cleared on day 42.
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Figure 40: 5-LO, 12-LO, and HDC mRNA expression in mouse lung tissue
Analysis of mouse lung tissue for the mRNA expression of 5-LO, 12-LO, and HDC revealed that
infected groups were the only one to express 12-LO from days 7-28 (A). 5-LO was expressed in
both infected groups on days 7-28 as well as AAD induced groups only on day 28 (A). By day
42 there was no expression of any of these mRNAs as a result of clearance of infection and
removal of AAD (B).
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Assessment of histamine production in BAL neutrophils
In order to determine if chlamydial infection could induce histamine production in
neutrophils, BAL neutrophils were purified from other cell types and then assessed for mRNA
expression of HDC using RT-PCR. Our data demonstrated that neutrophils isolated from infected
groups, regardless of AAD induction, had significant expression of HDC from day 7-28 (Figure
41A). Neutrophils from AAD induced only animals and uninfected animals had no expression of
HDC, even at day 28 when AAD was fully induced. By day 42 HDC was no longer detected as
a result of clearance of infection and alleviation of AAD (Figure 41B).
In addition to examining mRNA expression of HDC, purified BAL neutrophils were
stimulated in vitro with heat killed chlamydial antigens and were then assessed to see if this
elicited the release of histamine into the supernatant. Neutrophils from animals which had been
infected with Chlamydia released histamine in response to stimulation with chlamydial antigen
(Figure 42A). Histamine levels increased over time in response to antigen stimulation, and
peaked 72 mins post exposure. Stimulation of BAL neutrophils with SPG or J-cell macrophage
protein did not induce histamine release in any group (Figure 42B-C). Our data demonstrates that
chlamydial infection induces histamine production in BAL neutrophils, furthermore, direct
stimulation of these cells with chlamydial antigen causes subsequent histamine release.

Discussion
Besides well-defined environmental causes, accumulating evidence suggests that
respiratory tract infections play an important role in the pathogenesis of asthma. Among these,
Chlamydia pneumoniae infection has been discussed as a possible initiator in the development of
chronic asthma. Clinical studies have shown that early life C. pneumoniae infection is associated
with increased incidence of childhood asthma. Furthermore, this asthmatic phenotype is
characterized by infiltration of neutrophils, a phenomenon not seen in typical allergen-induced
airway hyperactivity which is characterized predominantly by eosinophils and basophils.
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Identifying host response factors that may contribute to the pathogenesis of airway
hyperreactivity (AHA) is critical for establishing a functional association between Chlamydiainduced airway inflammation and the subsequent development of persistent asthma. Surprisingly,
recent reports have found that almost 50% of persistent asthma cases are accompanied by an
increase in airway neutrophils and these patients were not only more refractory to corticosteroid
treatment, but represented the subset of asthmatics at greatest risk for asthma-related mortality. A
recent study carried out by Xu, et al demonstrated that Mycoplasma pneumoniae, a prevalent
respiratory pathogen that is commonly co-isolated with C. pneumoniae, provokes histamine
release from neutrophils in the murine airways (1). Indeed, neutrophils from infected murine
airways were highly enriched in histamine compared with naive neutrophils, and significantly
upregulated mRNA encoding histidine decarboxylase, the rate-limiting enzyme in histamine
synthesis (1). However, it is not clear which metabolite(s) represent the major neutrophil
chemoattractants in the infected airways of asthmatics.
Hepoxilins are biologically active metabolites of arachidonic acid that are formed
through the 12-lipoxygenase pathway. Hepoxilins were recently identified as potent neutrophil
chemoattractants in the intestinal mucosa, playing an even greater role than IL-8. Our goal in this
study was to determine if C. pneumoniae infection of the airways induce the release of
hepoxilins, to determine if hepoxilin is a neutrophil chemoattractant in the airway, and finally, to
determine if these neutrophils produce histamine in response to C. pneumoniae infection. We
therefore hypothesized that neutrophils, provoked by C. pneumoniae-induced lung infection,
undergo transmigration through an IL-8/hepoxilin gradient and greatly expand their capacity to
synthesize histamine, thereby contributing to airway inflammation and pathology.
Our data has demonstrated that chlamydial infection alone generates a Th1 type cytokine
response with corresponding macrophage and neutrophil infiltration. When AAD was induced a
mixed Th1/Th2 cytokine and cellular response was seen in infected animals. Uninfected AAD
controls responded with robust Th2 cytokine responses. These results are similar to those
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previously reported by Horvat et al (14) using a similar Ova mouse model. In addition, our
current study we found that infected animals also produced moderate levels of Th17 cytokines
(IL-17A, IL-23).

The presentation of these cytokines along with TNF-a are mediators of

neutrophil infiltration.
When we examined the lung tissue of our animals for the presence of hepoxilin (through
the detection of 12-lipoxygenase), we discovered that only Chlamydia infected mice expressed
12-LO protein and mRNA. Animals only induced for AAD or were uninfected did not produce
any 12-LO whatsoever. These data suggest that chlamydial infection is able to induce the
production of 12-LO as early as 7 days pi and strongly indicates that hepoxilin is a significant
chemoattractant for neutrophil infiltration. In addition, we also found that chlamydial infection
alone was also able to elicit mRNA expression of HDC indicating the production of histamine
production within the lung, providing potential for airway hyperresponsiveness.
In this study we also examined BAL neutrophils for the ability to produce histamine. We
found AAD induction alone, did elicit some neutrophil infiltration to the lung, but these cells
were not expressing HDC. Our infected animals regardless of AAD were characterized by
significant neutrophil infiltration and more interestingly, that these neutrophils were in fact
producing histamine in response to chlamydial infection. HDC upregulation was seen in BAL
neutrophils as early as 7 days pi, and was sustained until the infection had been resolved.
Furthermore upon stimulation of BAL neutrophils with chlamydial antigen caused histamine
degranulation from these cells. This data provides a mechanism as to how neutrophils can
mediate sudden and severe asthma airway hyperresponsiveness. Together this provides us insight
into how neutrophils can cause airway hyperresponsiveness as seen in asthma.
Ultimately this data demonstrates that chlamydial infection alone is able to induce a
slightly mixed Th1/Th17 cytokine response, marked by significant neutrophil infiltration. Our
data also indicates that neutrophil infiltration is mediated through the production of hepoxilin.
This alone is not indicative of a creating the typical Th2 driven allergic airway seen in asthmatics.
145

However, our data has shown that the population of neutrophils infiltrating the lung in response to
chlamydial infection are expressing HDC and producing histamine. This unique population of
neutrophils therein have the ability to create airway hyperresponsiveness by histamine
degranulation in response to chlamydial infection. We have provided an explanation as to how
neutrophilic asthma caused by a bacterial pathogen, can create an atopic airway and elicit sudden,
severe airway hyperresponsiveness in an asthmatic airway.
It is clear that neutrophils are the first cells recruited to the site of an allergic reaction;
they may influence clinical presentation and play a role in the development of severe chronic
asthma and the onset of sudden severe attacks. Our data has shown that if hepoxilin is released as
a consequence of infection, pharmacologic regulation of airway hepoxilin generation might
provide a novel and appropriate therapeutic strategy for a significant percentage of asthmatics
refractory to maximal doses of inhaled corticosteroid and are at increased risk for asthma
mortality. The data presented here has the potential to lead to new therapeutics (12-LO and 5-LO
antagonists) for hard to control asthma and/or for dampening lung inflammation.
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Figure 41: HDC mRNA expression in BAL neutrophils
Analysis purified BAL neutrophils for the mRNA expression of HDC demonstrated that infected
groups were the only one to express HDC from days 7-28 (A). HDC was not present in BAL
neutrophils in AAD only or uninfected groups. By day 42 there was no expression of any of
HDC a result of bacterial clearance (B).
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Figure 42: Histamine release from BAL neutrophils in response to chlamydial antigen
BAL neutrophils isolated from day 28 pi were challenged with chlamydial antigen in vitro and
subsequent histamine release into the supernatant was assessed using ELISA. BAL neutrophils
from infected animals released significant amounts of histamine in response to chlamydial
challenge which peaked 75 minutes post stimulation (A). Neutrophils from uninfected animals
had no release of histamine in response to chlamydial stimulation (A). Histamine release was not
seen in any group in response to stimulation with SPG or J-Cell protein (B, C).

148

References
1.

Xu X, Zhang D, Zhang H, Wolters PJ, Killeen NP, Sullivan BM, et al. Neutrophil
histamine contributes to inflammation in mycoplasma pneumonia. J Exp Med 2006.
203:2907-17.

2.

(ALA) ALA. Trends in Asthma Morbidity and Mortality. Epidemiology and Statistics
Unit Research and Program Services Division, 2010.

3.

Monteseirin J. Neutrophils and asthma. J Investig Allergol Clin Immunol 2009. 19:340-4.

4.

Chin AC, Parkos CA. Neutrophil transepithelial migration and epithelial barrier function
in IBD: potential targets for inhibiting neutrophil trafficking. Ann N Y Acad Sci 2006.
1072:276-87.

5.

Smith JA. Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc
Biol 1994; 56:672-86.

6.

Burns AR, Smith CW, Walker DC. Unique structural features that influence neutrophil
emigration into the lung. Physiol Rev 2003. 83:309-36.

7.

McCormick BA. Bacterial-induced hepoxilin A3 secretion as a pro-inflammatory
mediator. FEBS J 2007. 274:3513-8.

8.

Kucharzik T, Hudson JT, 3rd, Lugering A, Abbas JA, Bettini M, Lake JG, et al. Acute
induction of human IL-8 production by intestinal epithelium triggers neutrophil
infiltration without mucosal injury. Gut 2005.54:1565-72.

9.

Mrsny RJ, Gewirtz AT, Siccardi D, Savidge T, Hurley BP, Madara JL, et al.
Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil
migration across intestinal epithelia. Proc Natl Acad Sci U S A 2004. 101:7421-6.

10.

Reynaud D, Demin P, Pace-Asciak CR. Hepoxilin A3-specific binding in human
neutrophils. Biochem J 1996. 313 ( Pt 2):537-41.

11.

Hurley BP, Sin A, McCormick BA. Adhesion molecules involved in hepoxilin A3mediated neutrophil transepithelial migration. Clin Exp Immunol 2008. 151:297-305.

12.

Patel KK, Vicencio AG, Du Z, Tsirilakis K, Salva PS, Webley WC. Infectious
Chlamydia pneumoniae is associated with elevated interleukin-8 and airway neutrophilia
in children with refractory asthma. Pediatr Infect Dis J 2010. 29:1093-8.

13.

Webley WC, Salva PS, Andrzejewski C, Cirino F, West CA, Tilahun Y, et al. The
bronchial lavage of pediatric patients with asthma contains infectious Chlamydia. Am J
Respir Crit Care Med 2005. 171:1083-8.

14.

Horvat JC, Beagley KW, Wade MA, Preston JA, Hansbro NG, Hickey DK, Kaiko GE,
Gibson PG, Foster PS, Hansbro PM: Neonatal chlamydial infection induces mixed T-cell
responses that drive allergic airway disease. Am J Respir Crit Care Med 2007. 176:556564.

149

CHAPTER 7
DISCUSSION & CONCLUSIONS
Most clinical researchers agree that asthma is a serious multifactorial disease, and that
infectious agents play an important role in disease exacerbation. To date however, no specific
mechanism describing how infection of the airway might lead to asthma initiation or exacerbation
has been proposed. The data presented here initiates the first step in identifying the initial factors
by evaluating the host response to chlamydial infection in early life. This data, generated here,
serves multiple important purposes. First, we have established an effective animal model for
studying the initiation of allergic airway disease, opening up the way for studying other
respiratory pathogens such as RSV. Second, Chlamydia induces the production of cytokines that
lead to atopy in early life, thereby increasing the risk of developing asthma later in life, antibiotic
treatment to eliminate the bacteria would be highly desired early in life. This fact has the potential
to revolutionize the way pediatric patients with asthma are cared for. In addition to this, we have
observed that neutrophilic asthma phenotypes are becoming more prevalent and because of the
higher mortality in this patient group, it is necessary to better understand the mechanisms driving
inflammation. The data presented here demonstrates Chlamydia leads to histamine production
and release by neutrophils, this highlights a distinct mechanism of allergic asthma that does not
require mast cells and IgE antibodies typically seen in classical asthma (Figure 43). This means
that these patients would not benefit from popular treatments such as Omalizumab (Xolair) which
works by blocking IgE. Hepoxilins are indeed involved in neutrophil accumulation and
inflammation, this is could make a great therapeutic target that is worth further exploration.
Specifically we would determine the source of hepoxilin formation and release in the lungs. We
will also use mouse models to determine the exact contribution of neutrophils to histamine release
in the presence of Chlamydia by utilizing mast cell–deficient mice. As well as examine potential
therapeutics that specially target hepoxilin production.
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Figure 43: Classical vs. pathogen driven asthma
Classical asthma is based upon typical allergy to common allergens, which initiates asthma
symptomology through histamine production from mast cells and eosinophils. Which is typically
managed with cortico steroid treatment. Neutrophilic asthma is pathogen mediated and histamine
is produced in neutrophils. Effective treatement of neutrophilic asthma would be accomplished
via high dose antibiotics.
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